KR100473802B1 - Method of synthesizing β-amino-α-hydroxy carboxylic acid and its derivatives - Google Patents

Method of synthesizing β-amino-α-hydroxy carboxylic acid and its derivatives Download PDF

Info

Publication number
KR100473802B1
KR100473802B1 KR10-2001-0082479A KR20010082479A KR100473802B1 KR 100473802 B1 KR100473802 B1 KR 100473802B1 KR 20010082479 A KR20010082479 A KR 20010082479A KR 100473802 B1 KR100473802 B1 KR 100473802B1
Authority
KR
South Korea
Prior art keywords
group
formula
amino
compound
phenyl
Prior art date
Application number
KR10-2001-0082479A
Other languages
Korean (ko)
Other versions
KR20030052494A (en
Inventor
정성기
이재목
이창국
Original Assignee
학교법인 포항공과대학교
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 학교법인 포항공과대학교 filed Critical 학교법인 포항공과대학교
Priority to KR10-2001-0082479A priority Critical patent/KR100473802B1/en
Publication of KR20030052494A publication Critical patent/KR20030052494A/en
Application granted granted Critical
Publication of KR100473802B1 publication Critical patent/KR100473802B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

본 발명은 항균제, 항암제, 항생제, 소염제, 위궤양제, 동맥경화 치료제 및 면역억제제, 고혈압 치료제, 에이즈 치료제 등에 이용될 수 있는 β-아미노-α-히드록시 카르본산 및 그의 에스테르를 포함한 유도체의 제조 방법에 관한 것이다.The present invention is a method for producing a derivative including β-amino-α-hydroxy carboxylic acid and its esters that can be used in antibacterial, anticancer, antibiotic, anti-inflammatory, gastric ulcer, arteriosclerosis and immunosuppressive, hypertension, AIDS, etc. It is about.

본 발명에 따른 방법을 사용하면 하나의 출발물질로부터 두가지 β-아미노-α-히드록시 카르본산을 높은 입체 선택성으로 얻을 수 있다. 즉 아미노기의 보호기 종류를 달리함으로써 입체조절에 의한 환원 반응과 가교결합에 의한 환원 반응을 선택적으로 수행하여 syn과 anti 이성질체를 목적하는 바에 따라 얻을 수 있는 장점을 가지며 또한 반응 단계가 용이하고 수율이 우수하여 경제성이 매우 뛰어나다.Using the process according to the invention, two β-amino-α-hydroxy carboxylic acids can be obtained with high stereoselectivity from one starting material. That is, by changing the type of protecting group of the amino group, the reduction reaction by stereoregulation and the reduction reaction by crosslinking are selectively performed to obtain syn and anti isomers as desired, and the reaction step is easy and the yield is excellent. It is very economical.

Description

β-아미노-α-히드록시 카르본산 및 그 유도체의 제조 방법{Method of synthesizing β-amino-α-hydroxy carboxylic acid and its derivatives}Method for synthesizing β-amino-α-hydroxy carboxylic acid and its derivatives

본 발명은 β-아미노-α-히드록시 카르본산 및 그 유도체의 제조 방법에 관한 것으로, 보다 상세하게는 항균제, 항암제, 항생제, 소염제, 위궤양제, 동맥경화 치료제 및 면역억제제, 고혈압 치료제, 에이즈치료제 등에 이용될 수 있는 β-아미노-α-히드록시 카르본산 및 그의 에스테르를 포함한 유도체의 제조 방법에 관한 것이다.The present invention relates to a method for producing β-amino-α-hydroxy carboxylic acid and derivatives thereof, and more particularly, antibacterial, anticancer, antibiotic, anti-inflammatory, gastric ulcer, arteriosclerosis and immunosuppressant, hypertension, AIDS The present invention relates to a method for producing a derivative including β-amino-α-hydroxy carboxylic acid and esters thereof which can be used.

지금까지 문헌상에 알려진 광학적으로 순수한 β-아미노-α-히드록시 카르본산 및 그 유도체를 제조하는 방법으로는 비대칭 에폭시화 반응(J. Chem. Soc., Chem. Commun, 1994, 2767) 또는 비대칭 히드록시법을 이용하는 방법(J. Org. Chem. 1994, 59, 5104), 아미노산을 이용하는 방법(J. Org. Chem. 1991, 56, 6939), 베타 락탐 법(J. Org. Chem. 1991 , 56.,1681), 비대칭 알돌반응을 이용한 방법(J. Am. Chem. Soc. 1993, 115, 1151) 등이 있다. 그러나 이러한 방법들은 광학적, 입체적 선택성이 낮아 순수한 형태의 이성질체를 얻기에는 어려움이 있었다. 또한 반응단계수가 전체적으로 많을 뿐 아니라 극단적인 무수조건과 같이 반응 조건을 엄격하게 제어해야 하며 고가의 반응 시약을 사용하기 때문에 공업적인 측면에서 제한이 있었다. 특히 가장 큰 단점 중의 하나는 반응 조작을 통하여 하나의 출발물질로부터 서로 다른 광학 활성을 갖는 입체 이성질체를 순수한 형태로 얻기가 곤란하다.Methods of preparing optically pure β-amino-α-hydroxy carboxylic acids and derivatives thereof known so far include asymmetric epoxidation reactions ( J. Chem. Soc., Chem. Commun , 1994 , 2767) or asymmetrical hydrides. Method using the Roxy method ( J. Org. Chem . 1994 , 59 , 5104), Method using amino acids ( J. Org. Chem . 1991 , 56 , 6939), Beta lactam method ( J. Org. Chem . 1991 , 56 ., 1681), and methods using asymmetric aldol reactions ( J. Am. Chem. Soc . 1993 , 115 , 1151). However, these methods have difficulty in obtaining pure isomers due to their low optical and stereoselectivity. In addition, there are not only a large number of reaction stages as a whole, but also severe control of reaction conditions such as extreme anhydrous conditions, and use of expensive reaction reagents has limited industrial aspects. In particular, one of the biggest disadvantages is that it is difficult to obtain stereoisomers having different optical activities from one starting material in pure form through reaction reaction.

따라서, 본 발명이 이루고자 하는 기술적 과제는 이와 같은 문제들을 해결하여 하나의 출발물질로부터 서로 다른 광학 활성을 갖는 입체이성질체를 순수한 형태로 제조할 수 있으며, 반응단계수가 감소되고 수율이 양호한 실용적인 β-아미노-α-히드록시 카르본산 및 그 유도체의 제조방법을 제공하는 것이다.Accordingly, the technical problem to be solved by the present invention is to solve the above problems and to prepare stereoisomers having different optical activities from one starting material in a pure form, a practical β-amino having a reduced number of reaction steps and a good yield. It is to provide a method for producing -α-hydroxy carboxylic acid and its derivatives.

본 발명이 이루고자 하는 기술적 과제를 달성하기 위하여, 본 발명은 하기 화학식 2의 화합물의 산화반응에 의하여 화학식 1의 β-아미노-α-히드록시 카르본산 및 그 유도체를 제조하는 것을 특징으로 하는 방법을 제공한다:In order to achieve the technical problem to be achieved by the present invention, the present invention provides a method for producing a β-amino-α-hydroxy carboxylic acid and its derivatives of the formula (1) by oxidation of the compound to provide:

상기 식중, n은 0 또는 1이고,Wherein n is 0 or 1,

R1은 수소, C1-C8의 알킬기, 페닐기 또는 벤질기이고,R 1 is hydrogen, a C1-C8 alkyl group, a phenyl group or a benzyl group,

R2는 수소 또는 히드록시기의 보호기이고,R 2 is a protecting group of hydrogen or a hydroxy group,

R3는 수소 또는 아민기의 보호기이고,R 3 is a protecting group of hydrogen or an amine group,

R4는 C1-C20의 알킬기, C3-C20의 사이클로알킬기, 페닐기 또는 벤질기이며,R 4 is a C1-C20 alkyl group, a C3-C20 cycloalkyl group, a phenyl group or a benzyl group,

R5는 수소, C1-C10의 알킬기 또는 페닐기이며,R 5 is hydrogen, a C1-C10 alkyl group or a phenyl group,

X는 CH3COO, HCOO, HO2CCH(OH)CH(OH)COO, CH3SO3, CF3 CH3COO, CH3C6H5SO3, Cl, HSO4, 또는 H2PO4이고,X is CH 3 COO, HCOO, HO 2 CCH (OH) CH (OH) COO, CH 3 SO 3 , CF 3 CH 3 COO, CH 3 C 6 H 5 SO 3 , Cl, HSO 4 , or H 2 PO 4 ego,

*는 키랄탄소를 의미한다.* Means chiral carbon.

상기 화학식 2의 화합물은 하기 화학식 4의 화합물을 환원하여 합성될 수 있다:The compound of Formula 2 may be synthesized by reducing the compound of Formula 4 below:

상기 식중 R3, R4, 및 R5는 위에서 정의한 바와 같다.Wherein R 3 , R 4 , and R 5 are as defined above.

또한 본 발명은 하기 화학식 3의 화합물의 환원반응에 의하여 화학식 1의 β-아미노-α-히드록시 카르본산 및 그 유도체를 제조하는 것을 특징으로 하는 방법을 제공한다:The present invention also provides a method for preparing β-amino-α-hydroxy carboxylic acid of Formula 1 and its derivatives by reduction of a compound of Formula 3:

[화학식 1][Formula 1]

상기 식중, n은 0 또는 1이고,Wherein n is 0 or 1,

R1은 수소, C1-C8의 알킬기, 페닐기, 또는 벤질기이고,R 1 is hydrogen, a C1-C8 alkyl group, a phenyl group, or a benzyl group,

R2는 수소 또는 히드록시기의 보호기이고,R 2 is a protecting group of hydrogen or a hydroxy group,

R3는 수소 또는 아민기의 보호기이고,R 3 is a protecting group of hydrogen or an amine group,

R4는 C1-C20의 알킬기, C3-C20의 사이클로알킬기, 페닐기, 또는 벤질기이며,R 4 is a C1-C20 alkyl group, a C3-C20 cycloalkyl group, a phenyl group, or a benzyl group,

R5는 수소, C1-C10의 알킬기 또는 페닐기이며,R 5 is hydrogen, a C1-C10 alkyl group or a phenyl group,

X는 CH3COO, HCOO, HO2CCH(OH)CH(OH)COO, CH3SO3, CF3 CH3COO, CH3C6H5SO3, Cl, HSO4, 또는 H2PO4이고,X is CH 3 COO, HCOO, HO 2 CCH (OH) CH (OH) COO, CH 3 SO 3 , CF 3 CH 3 COO, CH 3 C 6 H 5 SO 3 , Cl, HSO 4 , or H 2 PO 4 ego,

*는 키랄탄소를 의미한다.* Means chiral carbon.

상기 화학식 3의 화합물은 하기 화학식 4의 화합물을 산화하여 합성될 수 있다:The compound of Formula 3 may be synthesized by oxidizing the compound of Formula 4.

[화학식 4][Formula 4]

상기 식중 R3, R4, 및 R5는 청구항 위에서 정의한 바와 같다.Wherein R 3 , R 4 , and R 5 are as defined above in the claims.

상기 산화시키는 단계는 O3, K2Cr2O7, Na2Cr2 O7, KMnO4, NaIO4, Pb(OC(=O)CH3)2, RuO4, H2O2, RuCl3, CrO3, (C5H5NH)2Cr2O7(PDC), 피리디움클로로크로메이트(PCC), NaClO2, Hg(OC(=O)CH3)2로 이루어진 군에서 선택된 하나 이상의 산화제를 이용하여 실시되는 것이 바람직하다.The oxidizing step is O 3 , K 2 Cr 2 O 7 , Na 2 Cr 2 O 7 , KMnO 4 , NaIO 4 , Pb (OC (= O) CH 3 ) 2 , RuO 4 , H 2 O 2 , RuCl 3 At least one oxidizing agent selected from the group consisting of: CrO 3 , (C 5 H 5 NH) 2 Cr 2 O 7 (PDC), pyridium chlorochromate (PCC), NaClO 2 , Hg (OC (= O) CH 3 ) 2 It is preferably carried out using.

상기 환원시키는 단계는 NaBH4, LiBH4, LiAlH4, L-셀렉트라이드, 디이소프로필알루미늄하이드라이드(DIBAL), Zn(BH4)2, (CH3)4BH(OC(=0)CH 3)3, NaBH3CN, LiBHEt3, LiAl(OC(=O)CH3)3로 이루어진 군에서 선택된 하나 이상의 환원제를 이용하여 실시되는 것이 바람직하다.The reducing step may include NaBH 4 , LiBH 4 , LiAlH 4 , L-selectide, diisopropylaluminum hydride (DIBAL), Zn (BH 4 ) 2 , (CH 3 ) 4 BH (OC (= 0) CH 3 ) 3, preferably NaBH 3 CN, LiBHEt 3, LiAl (OC (= O) CH 3) is carried out by using one or more reducing agents selected from the group consisting of 3.

상기 환원 반응시 부분입체선택성을 증가시키기 위하여 CeCl3, ZnCl2, NiCl2, 및 SmCl3로 이루어진 군에서 선택된 촉매가 더 부가되는 것이 바람직하다.In order to increase the diastereoselectivity in the reduction reaction, a catalyst selected from the group consisting of CeCl 3 , ZnCl 2 , NiCl 2 , and SmCl 3 is further added.

상기 C1-C8의 알킬기가 메틸, 에틸, 프로필, 이소프로필, n-부틸, 이소부틸, 및 t-부틸로 이루어진 군에서 선택된 그룹인 것이 바람직하다.The alkyl group of C 1 -C 8 is preferably a group selected from the group consisting of methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, and t-butyl.

상기 히드록시기의 보호기가 메톡시메틸, 메톡시티오메틸, 트리에틸실릴, 트리이소프로필실릴, t-부틸디페닐실릴, t-부틸디메틸실릴, 트리메틸실릴, 트리페닐실릴, 벤질, p-메톡시벤질, t-부톡시메틸, 테트라히드로피라닐, 3,4-디메톡시벤질, o-니트로벤질, 디페닐메틸, 및 트리페닐메틸로 이루어진 군에서 선택된 그룹인 것이 바람직하다.The protecting group of the hydroxy group is methoxymethyl, methoxythiomethyl, triethylsilyl, triisopropylsilyl, t-butyldiphenylsilyl, t-butyldimethylsilyl, trimethylsilyl, triphenylsilyl, benzyl, p-methoxybenzyl and t-butoxymethyl, tetrahydropyranyl, 3,4-dimethoxybenzyl, o-nitrobenzyl, diphenylmethyl, and triphenylmethyl.

상기 아민기의 보호기가 아세틸, 벤조일, 트리페닐메틸, 알릴, 디(4-메톡시페닐)메틸, N-5-디벤조수베릴, (4-메톡시페닐)디페닐페닐, 및 9-페닐플루오로레닐로 이루어진 군에서 선택된 그룹인 것이 바람직하다.The protecting group of the amine group is acetyl, benzoyl, triphenylmethyl, allyl, di (4-methoxyphenyl) methyl, N-5-dibenzosuberyl, (4-methoxyphenyl) diphenylphenyl, and 9-phenyl It is preferably a group selected from the group consisting of fluororenyl.

상기 C1-C20의 알킬기가 메틸, 에틸, 프로필 이소프로필 부틸, 이소부틸, t-부틸, 헥실, 및 헵틸로 이루어진 군에서 선택된 그룹인 것이 바람직하다.The alkyl group of C 1 -C 20 is preferably a group selected from the group consisting of methyl, ethyl, propyl isopropyl butyl, isobutyl, t-butyl, hexyl, and heptyl.

상기 C3-C20의 사이클로알킬기가 사이클로프로필, 사이틀로부틸, 사이클로펜틸, 및 사이클로헥실로 이루어진 군에서 선택된 그룹인 것이 바람직하다.The cycloalkyl group of C 3 -C 20 is preferably a group selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

본 발명의 제조방법에 따라 합성된 β-아미노-α-히드록시 카르본산 및 그 유도체는 광학적, 입체적으로 순수하여 의약품의 합성 중간체로서 사용될 수 있다.Β-amino-α-hydroxy carboxylic acid and derivatives thereof synthesized according to the preparation method of the present invention are optically and stericly pure and can be used as synthetic intermediates of pharmaceutical products.

이하, 본 발명에 따른 β-아미노-α-히드록시 카르본산 및 그 유도체의 제조방법을 상세히 설명한다.Hereinafter, a method for preparing β-amino-α-hydroxy carboxylic acid and its derivatives according to the present invention will be described in detail.

본 발명에 따른 화학식 1의 β-아미노-α-히드록시 카르본산 및 그 유도체는 화학식 2 내지 4 중에서 선택된 하나의 화합물의 산화반응, 환원반응에 의하여 제조된다:Β-amino-α-hydroxy carboxylic acid and derivatives thereof according to the present invention are prepared by oxidation, reduction of one compound selected from Formulas 2 to 4:

[화학식 1][Formula 1]

[화학식 3][Formula 3]

[화학식 4][Formula 4]

상기 식중, n은 0 또는 1이고,Wherein n is 0 or 1,

R1은 수소, C1-C8의 알킬기, 페닐기 또는 벤질기이고,R 1 is hydrogen, a C1-C8 alkyl group, a phenyl group or a benzyl group,

R2는 수소 또는 히드록시기의 보호기이고,R 2 is a protecting group of hydrogen or a hydroxy group,

R3는 수소 또는 아민기의 보호기이고,R 3 is a protecting group of hydrogen or an amine group,

R4는 C1-C20의 알킬기, C3-C20의 사이클로알킬기, 페닐기 또는 벤질기이며,R 4 is a C1-C20 alkyl group, a C3-C20 cycloalkyl group, a phenyl group or a benzyl group,

R5는 수소, C1-C10의 알킬기 또는 페닐기이며,R 5 is hydrogen, a C1-C10 alkyl group or a phenyl group,

X는 CH3COO, HCOO, HO2CCH(OH)CH(OH)COO, CH3SO3, CF3 CH3COO, CH3C6H5SO3, Cl, HSO4, 또는 H2PO4이고,X is CH 3 COO, HCOO, HO 2 CCH (OH) CH (OH) COO, CH 3 SO 3 , CF 3 CH 3 COO, CH 3 C 6 H 5 SO 3 , Cl, HSO 4 , or H 2 PO 4 ego,

*는 키랄탄소를 의미한다.* Means chiral carbon.

이를 하기 반응식 1을 참조하여 부연 설명하면, 화학식 1의 β-아미노-α-히드록시 카르본산 및 그 유도체는 하기 세가지 방법에 의하여 합성된다. 첫 번째 방법은 화학식 2의 화합물의 산화반응, 즉 (d) 단계를 통하여 제조하는 것이다. 두 번째 방법은 화학식 3의 환원반응, 즉 (c) 단계를 통하여 제조하는 것이다. 세 번째 방법은 화학식 4의 산화 환원반응, 즉 (c') 단계와 (d) 단계를 순차적으로 거치거나 (d') 단계 및 (c) 단계를 순차적으로 거침으로써 합성된다:This will be described further with reference to Scheme 1, β-amino-α-hydroxy carboxylic acid and its derivatives of Formula 1 are synthesized by the following three methods. The first method is to prepare the compound of formula 2 through the oxidation reaction, ie, step (d). The second method is to prepare a reduction reaction of Formula 3, ie, step (c). The third method is synthesized by redox reaction of Formula 4, i.e., step (c ') and step (d) sequentially or step (d') and step (c) sequentially:

여기서 화학식 1, 2, 3 및 4 로 표시되는 화합물에서 R1, R2, R3, R4 , 및 R5는 이미 전술한 바와 같다.Wherein R 1 , R 2 , R 3 , R 4 , and R 5 in the compounds represented by Formulas 1, 2, 3, and 4 are as described above.

상기 세가지 방법중, 세 번째 방법에 대하여 상세하게 살펴보면 다음과 같다. (c') 단계와 (d) 단계를 순차적으로 거치는 반응은 화학식 4의 화합물에서 케톤기를 환원한 후, 이중결합을 절단하여 카르본산으로 전환하는 방법이며, (d') 및 (c) 단계를 순차적으로 거치는 반응은 화학식 4의 화합물내에서의 이중결합을 절단하여 얻어진 알파 케토 에스테르, 즉 화학식 3의 화합물을 얻고, 이 화합물의 케톤기를 환원하는 방법이다.Among the three methods, the third method will be described in detail as follows. Step (c ') and step (d) is a step of sequentially reducing the ketone group in the compound of Formula 4, and then converting to carboxylic acid by cleaving the double bond, and (d') and Sequential reaction is a method of obtaining an alpha keto ester obtained by cleaving a double bond in a compound of formula 4, that is, a compound of formula 3, and reducing the ketone group of the compound.

상기 (c) 및 (c')의 환원 단계의 반응조건은 NaBH4, LiBH4, LiAlH4, L-셀렉트라이드, 디이소프로필알루미늄하이드라이드(DIBAL), Zn(BH4)2, Me4BH(OAc) 3, NaBH3CN, LiBHEt3, LiAl(OMe)3 등의 환원제를 이용하여 것이며, 상기 (d) 및 (d')의 산화 단계의 반응조건은 O3, K2Cr2O7, Na2Cr2 O7, KMnO4, NaIO4, Pb(OAc)2, RuO4, H2 O2, RuCl3, CrO3, (C5H5NH)2Cr2O7(PDC), 피리디움클로로크로메이트(PCC), NaClO2, Hg(OAc)2 등의 산화제를 이용하는 것이다.Reaction conditions of the reduction step of (c) and (c ') is NaBH 4 , LiBH 4 , LiAlH 4 , L-selectide, diisopropyl aluminum hydride (DIBAL), Zn (BH 4 ) 2 , Me 4 BH Reducing agents such as (OAc) 3 , NaBH 3 CN, LiBHEt 3 , LiAl (OMe) 3, etc., and the reaction conditions of the oxidation step of (d) and (d ′) are O 3 , K 2 Cr 2 O 7 , Na 2 Cr 2 O 7 , KMnO 4 , NaIO 4 , Pb (OAc) 2 , RuO 4 , H 2 O 2 , RuCl 3 , CrO 3 , (C 5 H 5 NH) 2 Cr 2 O 7 (PDC), An oxidizing agent such as pyridium chlorochromate (PCC), NaClO 2 and Hg (OAc) 2 is used.

상기 환원반응시 부분입체선택성(diastereoselectivity)을 증가시키기 위하여 첨가제로서 CeCl3, ZnCl2, NiCl2, SmCl3를 사용할 수 있다. 이때, 반응용매는 헥산, 벤젠, 톨루엔, 테트라히드로퓨란, 디옥산, 디메틸술폭시드, 아세토니트릴, 디클로로메탄, 클로로포름, 1,2-디클로로에탄, 에테르, 에틸아세테이트, 메탄올, 에탄올, 프로판올, 부탄올, t-부탄올 등을 사용할 수 있으며 반응온도는 50 ~ 100도가 바람직하다.CeCl 3 , ZnCl 2 , NiCl 2 , SmCl 3 may be used as an additive to increase diastereoselectivity in the reduction reaction. At this time, the reaction solvent is hexane, benzene, toluene, tetrahydrofuran, dioxane, dimethyl sulfoxide, acetonitrile, dichloromethane, chloroform, 1,2-dichloroethane, ether, ethyl acetate, methanol, ethanol, propanol, butanol, t-butanol and the like can be used, the reaction temperature is preferably 50 ~ 100 degrees.

상기 산화반응시, 반응용매로는 헥산, 벤젠, 톨루엔, 테트라히드로퓨란, 디옥산, 디메틸술폭시드, 아세토니트릴, 디클로로메탄, 클로로포름, 1,2-디클로로에탄, 에테르, 에틸아세테이트, 물, 메탄올, 에탄올, 프로판올, 부탄올, t-부탄올 등을 사용할 수 있다. In the oxidation reaction, the reaction solvent is hexane, benzene, toluene, tetrahydrofuran, dioxane, dimethyl sulfoxide, acetonitrile, dichloromethane, chloroform, 1,2-dichloroethane, ether, ethyl acetate, water, methanol, Ethanol, propanol, butanol, t-butanol and the like can be used.

상기 반응식 1에서, 화학식 4의 화합물은 공지의 화합물로서, 당해 기술분야에서의 통상적인 방법에 의하여 제조가능하다. 이와 같은 제조방법의 일예를 반응식 2에 나타낸다. 반응식 2에서 (a) 및 (b) 단계는 호너-워즈워스-에몬스 반응으로서, 에논 화합물을 효율적으로 제조할 수 있는 공지의 방법이다(Tetrahedron Lett. 1984, 25, pp 2183 및 Tetrahedron Lett. 1996, 37, pp 1077):In Scheme 1, the compound of Formula 4 is a known compound, and can be prepared by conventional methods in the art. An example of such a production method is shown in Scheme 2. Step (a) and (b) in Scheme 2 is a Horner-Words-Emons reaction, which is a known method for efficiently preparing an enone compound ( Tetrahedron Lett . 1984 , 25 , pp 2183 and Tetrahedron Lett . 1996 , 37 , pp 1077):

상기 반응식 2를 보다 상세히 설명하면, (a) 단계는 포스포네이트 중간체를 제조하는 단계로서 통상, 무수조건과 강염기를 사용한다. 상기 반응시 강염기로는 메틸리튬, n-부틸리튬, sec- 부틸리튬, t-부틸리튬 및 리튬디이소필아미드(LDA)를 사용하며, 용매는 불활성 용매로서 헥산, 벤젠, 톨루엔, 테트라히드로퓨란, 디옥산, 디메틸술폭시드, 아세토니트릴, 디클로로메탄, 클로로포름, 1,2-디클로로에탄, 에테르를 등을 사용할 수 있다. 반응온도는 -100~50℃가 가능하며 바람직하게는 -80~0℃가 적당하다. 이와 같은 방법에 따라 합성된 화학식 5의 화합물은 비교적 불안정하기 때문에 합성 후 곧바로 사용하여야 한다. Referring to Scheme 2 in more detail, step (a) is a step for preparing the phosphonate intermediate, usually using anhydrous conditions and strong bases. In the reaction, methyl lithium, n-butyllithium, sec-butyllithium, t-butyllithium and lithium diisophylamide (LDA) are used as the strong base, and the solvent is hexane, benzene, toluene, tetrahydrofuran, Dioxane, dimethyl sulfoxide, acetonitrile, dichloromethane, chloroform, 1,2-dichloroethane, ether and the like can be used. The reaction temperature is -100 ~ 50 ℃ is possible, preferably -80 ~ 0 ℃. The compound of formula 5 synthesized according to such a method is relatively unstable and should be used immediately after synthesis.

반응식 2의 (b) 단계에서, 화학식 4의 화합물은 화학식 5의 화합물과 R5CHO로 표시되는 알데히드 화합물을 염기조건에서 반응시켜 얻을 수 있다. 염기로는 메틸리튬, n-부틸리튬, sec-부틸리튬, t-부틸리튬, 소디움하이드라이드 및 리튬디이소필아미드(LDA) 등의 강염기 또는 트리에틸아민, N,N-디메틸아미노피리딘, 1,8-디아자비시클로운데센(DBU), 디이소프로필에틸아민, 탄산칼륨, 탄산나트륨, 탄산세슘 등의 약염기를 사용할 수 있다. 또한 반응속도를 증가시키기 위하여 염화리튬(LiCl)을 첨가제로 사용할 수 있다. 상기 (b) 단계에서의 반응 용매는 헥산, 벤젠, 톨루엔, 테트라히드로퓨란, 디옥산, 디메틸술폭시드, 아세토니트릴, 디클로로메탄, 클로로포름, 1,2-디클로로에탄, 에테르, 에틸아세테이트, 메탄올, 에탄올, 프로판올, 부탄올, t-부탄올 등을 사용할 수 있으며 반응온도는 바람직하게 -30∼80℃가 적당하다.In step (b) of Scheme 2, the compound of Formula 4 may be obtained by reacting a compound of Formula 5 with an aldehyde compound represented by R 5 CHO under basic conditions. Examples of the base include strong bases such as methyllithium, n-butyllithium, sec-butyllithium, t-butyllithium, sodium hydride and lithium diisophylamide (LDA) or triethylamine, N, N-dimethylaminopyridine, 1, Weak bases, such as 8-diazabicyclo undecene (DBU), diisopropylethylamine, potassium carbonate, sodium carbonate, cesium carbonate, can be used. In addition, lithium chloride (LiCl) may be used as an additive to increase the reaction rate. The reaction solvent in step (b) is hexane, benzene, toluene, tetrahydrofuran, dioxane, dimethyl sulfoxide, acetonitrile, dichloromethane, chloroform, 1,2-dichloroethane, ether, ethyl acetate, methanol, ethanol , Propanol, butanol, t-butanol and the like can be used, and the reaction temperature is preferably -30 to 80 ° C.

하기 반응식 3은 본 발명의 바람직한 일실시예에 따른 β-아미노-α-히드록시 카르본산 및 그 유도체 제조방법을 나타낸 것이다.Scheme 3 below shows a method for preparing β-amino-α-hydroxy carboxylic acid and its derivatives according to a preferred embodiment of the present invention.

상기 반응식 3에서 보는 바와 같이, 본 발명의 가장 큰 특징은 전술한 바와 같이 하나의 출발물질로부터 광학 활성을 갖는 두 가지 β-아미노-α-히드록시 카르본산을 높은 선택성으로 얻을 수 있다는 것이다. 즉, (D)-페닐글리신에서 유도된 에논(enone) 화합물을 환원하면 아미노기의 입체효과에 의하여 입체조절에 의한 환원 반응(sterically controlled reduction)이 진행되어 syn 화합물을 얻을 수가 있다. 그리고 에논 화합물을 먼저 오존 분해 반응 후 아미노기의 보호기를 제거하고 환원하면 아미노기에 의한 가교 결합에 의한 환원반응(chealation controlled reduction)이 진행되어 anti 화합물을 선택적으로 얻을 수가 있다(참고문헌; Mengel, A.; Reiser, O. Chem. Rev. 1999, 99, 1191; Marshall, J. A.; Garofalo, A. W. J. Org. Chem. 1993, 58, 3675).As shown in Scheme 3, the biggest feature of the present invention is that, as described above, two β-amino-α-hydroxy carboxylic acids having optical activity can be obtained with high selectivity from one starting material. In other words, when the enone compound derived from (D) -phenylglycine is reduced, a steric controlled reduction by a steric effect of the amino group proceeds, thereby obtaining a syn compound. In addition, if the enone compound is first removed after ozone decomposition, the protecting group of the amino group is removed, and then reduced, a reduction reaction (chealation controlled reduction) by cross-linking by the amino group proceeds, thereby obtaining an anti compound selectively (Ref. Mengel, A. Reiser, O. Chem. Rev. 1999 , 99 , 1191; Marshall, JA; Garofalo, AW J. Org. Chem . 1993 , 58 , 3675).

이하 본 발명을 참고예와 실시예를 들어 보다 상세히 설명하되, 이들은 예시적인 것에 불과하며, 본 발명의 범위를 한정하지 않는다.Hereinafter, the present invention will be described in more detail with reference to Examples and Examples, which are merely illustrative and do not limit the scope of the present invention.

[실시예]EXAMPLE

참고예 1. (D)-Reference Example 1. (D)- NN -(트리틸아미노)페닐글리신 메틸에스테르의 제조방법Method for preparing-(tritylamino) phenylglycine methyl ester

MeOH (200 ml)을 빙욕조로 냉각하고 아세틸클로라이드(AcCl) (61 g, 598 mmol)를 20 분간 적가하고 5 분 더 교반하였다. 빙욕조를 제거하고 20 분간 교반 후 D-페닐글리신(26.0 g, 172 mmol)을 가하고 3시간 환류 교반하였다. 반응화합물을 감압증류하여 용매 대부분을 제거하고 에틸아세테이트(EtOAc, 200 ml)를 넣고 교반한 후 고체를 여과, 건조하여 (D)-페닐글리신 메틸에스테르 염산염(34 g, 98%)를 얻었다. MeOH (200 ml) was cooled in an ice bath and acetylchloride (AcCl) (61 g, 598 mmol) was added dropwise for 20 minutes and stirred for another 5 minutes. The ice bath was removed, stirred for 20 minutes, and then D-phenylglycine (26.0 g, 172 mmol) was added thereto, followed by stirring at reflux for 3 hours. The reaction compound was distilled under reduced pressure to remove most of the solvent, and ethyl acetate (EtOAc, 200 ml) was added thereto, followed by stirring. The solid was filtered and dried to obtain (D) -phenylglycine methyl ester hydrochloride (34 g, 98%).

CH2Cl2 (150 ml)에 (D)-페닐글리신 메틸에스테르 염산염 (10.0 g, 49.6 mmol)과 Et3N(11.0 g, 109 mmol)을 넣고 빙욕조로 냉각하였다. 이어서 반응화합물에 PPh3Cl (13.8 g, 49.6 mmol)을 넣고 상온에서 하루 밤 교반하였다. 물을 넣고 추출 후 유기층을 건조하고 감압 증류하여 거품형의 고체를 얻었다. 이 고체를 90%-EtOH로 재결정하여 흰색 결정 (D)-N-(트리틸아미노)페닐글리신 메틸에스테르(19 g, 94%)를 얻었다.(D) -phenylglycine methyl ester hydrochloride (10.0 g, 49.6 mmol) and Et 3 N (11.0 g, 109 mmol) were added to CH 2 Cl 2 (150 ml), and the mixture was cooled in an ice bath. Subsequently, PPh 3 Cl (13.8 g, 49.6 mmol) was added to the reaction compound, and the mixture was stirred at room temperature overnight. After adding water and extracting, the organic layer was dried and distilled under reduced pressure to obtain a foamy solid. The obtained solid was recrystallized with 90% -EtOH determines white (D) - N - (trityl) phenyl glycine methyl ester (19 g, 94%) was obtained.

mp 132-133℃; mp 132-133 ° C .;

[α]D 25 153.80 (c 0.92, CHCl3);[α] D 25 153.80 (c 0.92, CHCl 3 );

1H NMR (CDCl3) 7.43- 7.05 (m, 20 H), 4.30 (s, 1 H), 3.27 (br s, 1 H), 3.04 (s, 3 H). 1 H NMR (CDCl 3 ) 7.43- 7.05 (m, 20 H), 4.30 (s, 1 H), 3.27 (br s, 1 H), 3.04 (s, 3 H).

참고예 2. (L)-Reference Example 2. (L)- NN -(트리틸아미노)페닐알라닌 메틸에스테르의 제조방법Method for preparing-(tritylamino) phenylalanine methyl ester

참고예 1의 (D)-N-(트리틸아미노)페닐글리신 메틸에스테르의 합성법과 동일한 방법으로 (L)-페닐알라닌(8.0 g, 37 mmol)에서 출발하여 (L)-N-(D)-N-(트리틸아미노)페닐알라닌 메틸에스테르(14.7 g, 94%)를 얻었다.Reference Example 1 (D) - N - a (trityl-amino) phenyl glycine methyl ester In the same manner as Synthesis Method (L) - from phenylalanine (8.0 g, 37 mmol) ( L) - N - (D) - N - ( trityl-amino) phenylalanine methyl ester (14.7 g, 94%) was obtained.

mp 90-91℃; mp 90-91 ° C .;

[α]D 25 +44.63 (c 0.87, CHCl3);[a] D 25 +44.63 (c 0.87, CHC1 3 );

1H NMR (CDCl3) 7.44-7.17 (m, 20 H), 3.59 (t, J=6.8 Hz, 1 H), 3.06 (s, 3 H), 2.98 (m, 2 H), 2.67 (br s, 1 H). 1 H NMR (CDCl 3 ) 7.44-7.17 (m, 20 H), 3.59 (t, J = 6.8 Hz, 1 H), 3.06 (s, 3 H), 2.98 (m, 2 H), 2.67 (br s , 1 H).

참고예 3. (L)-Reference Example 3. (L)- NN -(트리틸아미노)루이신 메틸에스테르의 제조방법Method for preparing-(tritylamino) leucine methyl ester

참고예 1의 (D)-N-(트리틸아미노)페닐글리신 메틸에스테르의 합성법과 동일한 방법으로 (L)-루이신(5.0 g, 38.1 mmol)에서 출발하여 (L)-N-(트리틸아미노)루이신 메틸에스테르(12.7 g, 86%)를 얻었다.Reference Example 1 (D) - N - (trityl-amino) In a similar manner to the phenyl synthesis of glycine methyl ester (L) - leucine from (5.0 g, 38.1 mmol) ( L) - N - ( trityl Amino) leucine methyl ester (12.7 g, 86%) was obtained.

mp 84-85℃; mp 84-85 ° C .;

[α]D 25 +52.65 (c 0.83, CHCl3);[α] D 25 +52.65 (c 0.83, CHCl 3 );

1H NMR (CDCl3) 7.55-7.16 (m, 15 H), 3.37 (pseudo t, 1 H), 3.16 (s, 3 H), 2.73 (br s, 1 H), 1.63 (m, 3 H), 0.91 (dd, J=7.7, 6.1 Hz, 6 H). 1 H NMR (CDCl 3 ) 7.55-7.16 (m, 15 H), 3.37 (pseudo t, 1 H), 3.16 (s, 3 H), 2.73 (br s, 1 H), 1.63 (m, 3 H) , 0.91 (dd, J = 7.7, 6.1 Hz, 6H).

참고예 4. (1Reference Example 4. (1 R,R, 33 EE )-1,4-디페닐-1-(트리틸아미노)-부트-3-엔-2-온의 제조방법Method for preparing) -1,4-diphenyl-1- (tritylamino) -but-3-en-2-one

테트라히드로퓨란 100ml에 디메틸메틸포스포네이트 3.0g(24.6mmol)을 가한 후 -78℃로 냉각하였다. n-부틸리튬(1.6M) 15ml(24.6mmol)를 10분간 적가하였다. 같은 온도에서 10분간 더 교반한 후 참고예 1에서 얻은 (D)-N-(트리틸아미노)페닐글리신 메틸에스테르 2.0g(4.87mmol)를 테트라히드로퓨란 10ml에 용해한 용액을 위의 냉각된 용액에 10분간 적가하였다. 같은 온도에서 3시간 교반한 후 포화 암모늄용액 80ml를 주의해서 가한 후 에틸아세테이트 100ml를 넣고 추출하였다. 유기층을 취하여 물로 세척하고 황산마그네슘으로 건조하였다. 실리카겔 컬럼으로 분리하여 2.3g의 포스포네이트 중간체를 시럽형태로 얻었다.To 100 ml of tetrahydrofuran was added 3.0 g (24.6 mmol) of dimethylmethylphosphonate and cooled to -78 ° C. 15 ml (24.6 mmol) of n-butyllithium (1.6 M) was added dropwise for 10 minutes. N - - (D) obtained in the reference after 10 minutes further stirring at the same temperature for Example 1, a solution obtained by dissolving a (trityl-amino) phenyl glycine methyl ester 2.0g (4.87mmol) in 10ml of tetrahydrofuran in a cooled solution of the above 10 minutes was added dropwise. After stirring for 3 hours at the same temperature, 80 ml of saturated ammonium solution was carefully added, and 100 ml of ethyl acetate was added thereto. The organic layer was taken, washed with water and dried over magnesium sulfate. Separation by silica gel column gave 2.3 g of phosphonate intermediate in the form of syrup.

여기에 THF (60 ml)와 PhCHO (0.58 g, 5.5 mmol)을 넣고 빙욕조로 냉각하였다. 60% NaH(0.22 g, 5.7 mmol)을 3 회에 나누어 가하고 상온에서 16시간 교반하였다. 반응액을 얼음물에 붓고 EtOAc로 추출하였다. 유기층을 건조하고 감압증류하여 노란색의 시럽을 얻었으며 대기중에 방치시 고체화 되었다. 90%-EtOH로 재결정하여 연노랑색 결정으로서 상기 표제 화합물 (1R,3E)-1,4-디페닐-1-(트리틸아미노)-부트-3-엔-2-온 (1.9 g, 88%)를 얻었다.THF (60 ml) and PhCHO (0.58 g, 5.5 mmol) were added thereto and cooled in an ice bath. 60% NaH (0.22 g, 5.7 mmol) was added in three portions and stirred at room temperature for 16 hours. The reaction solution was poured into iced water and extracted with EtOAc. The organic layer was dried and distilled under reduced pressure to yield a yellow syrup, which solidified when left in the air. 90% recrystallized from -EtOH to afford the title compound as a pale yellow crystal (1 R, 3 E) -1,4- diphenyl-1- (trityl-amino) boot-3-en-2-one (1.9 g, 88%).

mp 95-96℃;mp 95-96 ° C .;

[α]D 25 134.6 (c 1.03, CHCl3);[α] D 25 134.6 (c 1.03, CHCl 3 );

IR (NaCl film) 3027, 1686, 1610, 1449 cm-1;IR (NaCl film) 3027, 1686, 1610, 1449 cm −1 ;

1H NMR (CDCl3) 7.55-7.12 (m, 21 H, 올레핀 CH 포함), 2.68 (dd, J=15.9, 6.2 Hz, 1 H), 4.70 (d, J=5.6 Hz, 1 H), 4.15 (br s, 1 H). 1 H NMR (CDCl 3 ) 7.55-7.12 (m, 21 H, with olefin CH), 2.68 (dd, J = 15.9, 6.2 Hz, 1 H), 4.70 (d, J = 5.6 Hz, 1 H), 4.15 (br s, 1 H).

참고예 5. (1Reference Example 5. (1 R,R, 33 EE )-1-페닐-1-(트리틸아미노)-펜트-3-엔-2온의 제조 방법Method for producing) -1-phenyl-1- (tritylamino) -pent-3-en-2one

참고예 1에서 얻은 출발물질 (D)-N-(트리틸아미노)페닐글리신 메틸에스테르 ( 11.25 mmol)를 사용하여 참고예 4와 동일한 방법으로 포스포네이트 유도체를 만들고 여기에 CH3CHO로 축합하여 흰색 결정으로서 상기 표제 화합물 (1R,3E)-1-페닐-1-(트리틸아미노)-펜트-3-엔-온 (4.0 g, 85%)를 얻었다.Note the starting material obtained in Example 1 (D) - N - (trityl) phenyl creates a glycine methyl ester (11.25 mmol) and Reference Example 4 and phosphonate derivatives in the same manner using a condensing to CH 3 CHO here The title compound ( 1R, 3E ) -1-phenyl-1- (tritylamino) -pent-3-en-one (4.0 g, 85%) was obtained as white crystals.

mp 117-118.5℃; mp 117-118.5 ° C .;

[α]D 25 240.0 (c 1.06, CHCl3);[α] D 25 240.0 (c 1.06, CHCl 3 );

1H NMR (CDCl3) 7.46-7.10 (m, 20 H), 6.37 (dt, J=15.6, 6.9 Hz, 1 H), 5.64 (dd, J=15.5, 1.4 Hz, 1 H), 4.53 (s, 1 H), 4.05 (br s, 1 H), 1.59 (dd, J=6.9, 1.6 Hz, 3 H). 1 H NMR (CDCl 3 ) 7.46-7.10 (m, 20 H), 6.37 (dt, J = 15.6, 6.9 Hz, 1 H), 5.64 (dd, J = 15.5, 1.4 Hz, 1 H), 4.53 (s , 1 H), 4.05 (br s, 1 H), 1.59 (dd, J = 6.9, 1.6 Hz, 3 H).

참고예 6. (4Reference Example 6. (4 SS ,1,One EE )-1,5-디페닐-4-(트리틸아미노)-펜트-1-엔-3온의 제조방법Method for preparing 1,5-diphenyl-4- (tritylamino) -pent-1-en-3one

참고예 2에서 얻은 출발물질 (L)-N-(트리틸아미노)페닐알라민 메틸에스테르 (2.57 mmol)를 사용하여 참고예 4와 동일한 방법으로 포스포네이트 유도체를 만들고 여기에 PhCHO로 축합하여 노란색의 무정형 고체로서 상기 표제 화합물 (4S,1E)-1,5-디페닐-4-(트리틸아미노)-펜트-1-엔-3-온 (1.09g, 86%)을 얻었다.Note the starting material obtained in Example 2 (L) - N - (trityl) phenyl Allah Min making the methyl ester (2.57 mmol) and Reference Example 4 and phosphonate derivatives in the same manner using the yellow and condensed with PhCHO here The title compound (4S , 1 E ) -1,5-diphenyl-4- (tritylamino) -pent-1-en-3-one (1.09 g, 86%) was obtained as an amorphous solid of.

[α]D 25 +88.39 (c 0.56, CHCl3);[α] D 25 +88.39 (c 0.56, CHCl 3 );

1H NMR (CDCl3) 7.48-6.90 (m, 25 H), 6.92 (d, J=16.0 Hz, 1 H), 6.07 (d, J=16.0 Hz, 1 H), 3.97 (t, J=6.6 Hz, 1 H), 3.25 (br s, 1 H), 2.98 (m, 2 H). 1 H NMR (CDCl 3 ) 7.48-6.90 (m, 25 H), 6.92 (d, J = 16.0 Hz, 1 H), 6.07 (d, J = 16.0 Hz, 1 H), 3.97 (t, J = 6.6 Hz, 1H), 3.25 (br s, 1H), 2.98 (m, 2H).

참고예 7. (4Reference Example 7. (4 SS ,1,One EE )-6-메틸-1-페닐-4-(트리틸아미노)-헵트-1-엔-3-온의 제조방법Method for preparing) -6-methyl-1-phenyl-4- (tritylamino) -hept-1-en-3-one

참고예 3에서 얻은 출발물질 (3.86 mmol)에서 출발하여 참고예 4와 동일한 방법으로 포스포네이트 유도체를 만들고 여기에 PhCHO로 축합하여 노란색의 결정성 고체로서 상기 표제 화합물 (4S,1E)-6-메틸-1-페닐-4-(트리틸아미노)-헵트-1-엔-3-온 (1.33 g, 75%)를 얻었다.Reference Example 3 The starting material (3.86 mmol) in Reference Example 4 in the same manner as in making the phosphonate derivative afforded the title compound as a crystalline solid with yellow by condensation with PhCHO here (4 S, 1 E) from obtained from the - 6-Methyl-1-phenyl-4- (tritylamino) -hept-1-en-3-one (1.33 g, 75%) was obtained.

mp 103-105℃; mp 103-105 ° C .;

[α]D 25 +119.17 (c 0.97, CHCl3);[α] D 25 +119.17 (c 0.97, CHC1 3 );

1H NMR (CDCl3) 7.55-7.05 (m, 21 H), 6.30 (d, J=16.0 Hz, 1 H), 3.71 (t, J=6.8 Hz, 1 H), 1.75 (m, 1 H), 1.54 (t, J=6.8 Hz, 2 H), 0.92 (dd, J=6.5, 1.6 Hz, 6 H). 1 H NMR (CDCl 3 ) 7.55-7.05 (m, 21 H), 6.30 (d, J = 16.0 Hz, 1 H), 3.71 (t, J = 6.8 Hz, 1 H), 1.75 (m, 1 H) , 1.54 (t, J = 6.8 Hz, 2H), 0.92 (dd, J = 6.5, 1.6 Hz, 6H).

참고예 8. (1Reference Example 8. (1 R,R, 33 EE )-1-아미노-1,4-디페닐-부트-3-엔-2-온 염산염의 제조방법) -1-amino-1,4-diphenyl-but-3-en-2-one hydrochloride

THF (10 ml)에 참고예 4에서 얻은 (1R, 3E)-1,4-디페틸-1-(트리틸아미노)-부트-3-엔-2-온 (0.61 g, 1.27 mmol)를 가한 후 conc-HCl (0.3 ml)을 넣었다. 상온에서 1 시간 교반 후 TLC로 출발물질이 사라진 것을 확인하고 Et2O (10 ml)를 넣었다. 석출된 고체를 여과하고 EtOAc로 세척 후 건조하여 상기의 표제 화합물 (1R,3E)-1-아미노-1,4-디페닐-부트-3-엔-2-온 염산염을 흰색의 결정 (0.33 g, 95%)으로 얻었다.(1 R, 3 E) -1,4- diphenoxylate butyl-1- (trityl-amino) obtained reference in THF (10 ml) in Example 4-a boot-3-en-2-one (0.61 g, 1.27 mmol) After adding conc-HCl (0.3 ml) was added. After stirring for 1 hour at room temperature, the starting material disappeared by TLC, and Et 2 O (10 ml) was added thereto. The precipitated solid was filtered off and then washed and dried to the title compound (1 R, 3 E) -1- amino-1,4-phenylene with EtOAc - Boot-3-en-2-one hydrochloride White crystals of ( 0.33 g, 95%).

mp >188℃ (dec.);mp> 188 ° C. (dec.);

[α]D 25 61.91 (c 0.97, MeOH);[α] D 25 61.91 (c 0.97, MeOH);

1H NMR (CD3OD) 7.79 (d, J=16.0, 1 H), 7.55-7.33 (m, 10 H), 6.81 (d, J=16.0 Hz, 1 H), 5.57 (d, J=2.5 Hz, 1 H). 1 H NMR (CD 3 OD) 7.79 (d, J = 16.0, 1 H), 7.55-7.33 (m, 10 H), 6.81 (d, J = 16.0 Hz, 1 H), 5.57 (d, J = 2.5 Hz, 1 H).

참고예 9. (1Reference Example 9. (1 R,R, 33 EE )-1-아미노-1-페닐-펜트-3-엔-2-온 염산염의 제조방법) -1-amino-1-phenyl-pent-3-en-2-one hydrochloride

참고예 8과 동일한 방법으로 참고예 5에서 얻은 (1R,3E)-1-페닐-1-(트리틸아미노)-펜트-3-엔-2-온에서 출발하여 제조하였다. (수율 90%, 무색 결정).Note in the same manner as in Example 8 obtained in Example 5 (1 R, 3 E) -1-phenyl-1 (trityl-amino) pent-3-ene was prepared from 2-one. (Yield 90%, colorless crystals).

mp >165℃ (dec.);mp> 165 ° C. (dec.);

[α]D 25 184.20 (c 1.01, MeOH);[a] D 25 184.20 (c 1.01, MeOH);

1H NMR (CD3OD) 7.48-7.42 (m, 5 H), 7.09 (dt, J=15.6, 6.9 Hz, 1 H), 6.13 (dd, J=15.6, 1.6 Hz, 1 H), 5.44 (s, 1 H), 1.80 (dd, J=6.9, 1.6 Hz, 3 H). 1 H NMR (CD 3 OD) 7.48-7.42 (m, 5H), 7.09 (dt, J = 15.6, 6.9 Hz, 1 H), 6.13 (dd, J = 15.6, 1.6 Hz, 1 H), 5.44 ( s, 1 H), 1.80 (dd, J = 6.9, 1.6 Hz, 3 H).

참고예 10. (4Reference Example 10. (4 S,S, 1One EE )-4-아미노-1,5-디페닐-1-펜트-1-엔-3-온 염산염의 제조방법Method for preparing 4-amino-1,5-diphenyl-1-pent-1-en-3-one hydrochloride

참고예 8과 동일한 방법으로 참고예 6에서 얻은 (4S,1E)-1,5-디페닐-4-(트리틸아미노)-펜트-1-엔-3-온에서 출발하여 제조하였다(수율 96%, 무색 결정).Prepared from (4 S, 1 E ) -1,5-diphenyl-4- (tritylamino) -pent-1-en-3-one obtained in Reference Example 6 in the same manner as Reference Example 8 Yield 96%, colorless crystals).

mp >195℃ (dec.);mp> 195 ° C. (dec.);

[α]D 25 +34.28 (c 0.77, MeOH);[α] D 25 +34.28 (c 0.77, MeOH);

1H NMR (CD3OD) 7.70 (d, J=16.0 Hz, 1 H), 7.59-7.31 (m, 10 H), 6.89 (d, J=16.0 Hz, 1 H), 4.75 (t, J=6.9 Hz, 1 H), 3.23 (m, 1 H). 1 H NMR (CD 3 OD) 7.70 (d, J = 16.0 Hz, 1 H), 7.59-7.31 (m, 10 H), 6.89 (d, J = 16.0 Hz, 1 H), 4.75 (t, J = 6.9 Hz, 1 H), 3.23 (m, 1 H).

참고예 11. (4Reference Example 11. (4 S,S, 1One EE )-4-아미노-6-메틸-1-페닐-헵트-1-엔-3-온 염산염의 제조방법Method of preparing 4-amino-6-methyl-1-phenyl-hept-1-en-3-one hydrochloride

참고예 8과 동일한 방법으로 참고예 7에서 얻은 (4S,1E)-6-메틸-1-페닐-4-(트리틸아미노)-헵트-1-엔-3-온에서 출발하여 제조하였다(수율 99%, 무색 결정).Prepared from ( 4S , 1E ) -6-methyl-1-phenyl-4- (tritylamino) -hept-1-en-3-one obtained in Reference Example 7 in the same manner as Reference Example 8. (Yield 99%, colorless crystals).

mp >162℃ (dec.);mp> 162 ° C. (dec.);

[α]D 25 +21.98 (c 0.48, MeOH);[α] D 25 +21.98 (c 0.48, MeOH);

1H NMR (CD3OD) 7.81 (d, J=16.0 Hz, 1 H), 7.72-7.41 (m, 5 H), 7.05 (d, J=16.0 Hz, 1 H), 4.44 (dd, J=9.5, 3.8 Hz, 1 H), 1.80 (m, 2 H), 1.65 (m, 1 H), 1.04 (dd, J=7.1, 6.0 Hz, 6 H). 1 H NMR (CD 3 OD) 7.81 (d, J = 16.0 Hz, 1 H), 7.72-7.41 (m, 5H), 7.05 (d, J = 16.0 Hz, 1 H), 4.44 (dd, J = 9.5, 3.8 Hz, 1 H), 1.80 (m, 2 H), 1.65 (m, 1 H), 1.04 (dd, J = 7.1, 6.0 Hz, 6 H).

실시예 1. (1Example 1. (1 RR ,2,2 R,R, 33 EE )-1,4-디페닐-1-(트리틸아미노)-부트-3-엔-2-올의 제조방법Method for preparing 1,4-diphenyl-1- (tritylamino) -but-3-en-2-ol

CH2Cl2 (0.6 ml)에 참고예 4에서 얻은 (1R,3E)-1,4-디페닐-1-(트리틸아미노)-부트-3-엔-2-온 (57 mg, 0.11 mmol)를 넣어 녹이고 MeOH (2 ml)를 가하고 빙욕조로 냉각하였다. CeCl3ㆍ7H2O (82 mg, 0.22 mmol)를 가하고 5 분 동안 교반 후 NaBH4(17 mg, 0.45 mmol)를 넣었다. 같은 온도에서 3 시간 후 물과 EtOAc를 가하고 추출하였다. 유기층을 건조 후 감압 증류하여 시럽을 얻었으며 CHCl3/MeOH (1/5)의 혼합 용매로 재결정하여 상기 표제 화합물 (1R,2R,3E)-1,4-디페닐-1-(트리틸아미노)-부트-3-엔-2-올을 흰색의 결정 (28 mg, 50%)으로 얻었다.(1 R, 3 E ) -1,4-diphenyl-1- (tritylamino) -but-3-en-2-one (57 mg, in CH 2 Cl 2 (0.6 ml) obtained in Reference Example 4 0.11 mmol) was added to dissolve it, MeOH (2 ml) was added thereto, and the mixture was cooled in an ice bath. CeCl 3 · 7H 2 O (82 mg, 0.22 mmol) was added and stirred for 5 minutes followed by NaBH 4 (17 mg, 0.45 mmol). After 3 hours at the same temperature, water and EtOAc were added and extracted. The organic layer was dried and dried under reduced pressure to obtain a syrup, and recrystallized with a mixed solvent of CHCl 3 / MeOH (1/5) to obtain the title compound (1 R , 2 R, 3 E ) -1,4-diphenyl-1- ( Tritylamino) -but-3-en-2-ol Obtained as white crystals (28 mg, 50%).

mp 211-213℃; mp 211-213 ° C;

[α]D 25 +33.13 (c 1.02, CHCl3);[α] D 25 +33.13 (c 1.02, CHCl 3 );

IR (NaCl film) 3028, 1492, 1448 cm-1;IR (NaCl film) 3028, 1492, 1448 cm −1 ;

1H NMR (CDCl3); 7.46-6.96 (m, 25 H), 6.31 (d, J=15.9 Hz, 1 H), 5.85 (dd, J=15.9, 6.9 Hz, 1 H), 6.90 (d, J=6.6 Hz, 1 H), 3.75 (d, J=6.6 Hz, 1 H). 1 H NMR (CDCl 3 ); 7.46-6.96 (m, 25H), 6.31 (d, J = 15.9 Hz, 1 H), 5.85 (dd, J = 15.9, 6.9 Hz, 1 H), 6.90 (d, J = 6.6 Hz, 1 H) , 3.75 (d, J = 6.6 Hz, 1 H).

실시예 2. (1Example 2. (1 RR ,2,2 R,R, 33 EE )-1-페닐-1-(트리틸아미노)-펜트-3-엔-2-올의 제조방법Method for preparing) -1-phenyl-1- (tritylamino) -pent-3-en-2-ol

참고예 5에서 얻은 (1R,3E)-1-페닐-1-(트리틸아미노)-펜트-3-엔-2-온을 사용하여 실시예 1과 동일한 방법으로 상기의 표제 화합물 (2R,3R,3E)-1-페닐-1-(트리틸아미노)-펜트-3-엔-2-올 (75%, 무색 결정)을 얻었다.Note obtained in Example 5 (1 R, 3 E) -1-phenyl-1 (trityl-amino) pent-3-ene in the same manner as in Example 1 by using 2-one The title compound of (2 R , 3R, 3E ) -1-phenyl-1- (tritylamino) -pent-3-en-2-ol (75%, colorless crystals) was obtained.

mp 103-104.5℃; mp 103-104.5 ° C .;

[α]D 25 48.52 (c 1.40, CHCl3);[α] D 25 48.52 (c 1.40, CHCl 3 );

1H NMR (CDCl3) 7.46-6.96 (m, 20 H), 5.35 (dt, J=15.3, 6.4 Hz, 1 H), 5.11 (ddd, J=15.3, 7.6, 1.5 Hz, 1 H), 3.77 (d, J=6.5 Hz, 1 H), 3.39 (t, J=7.0 Hz, 1 H), 2.39 (br, 2 H), 1.57 (dd, J=6.4, 1.0 Hz, 3 H). 1 H NMR (CDCl 3 ) 7.46-6.96 (m, 20 H), 5.35 (dt, J = 15.3, 6.4 Hz, 1 H), 5.11 (ddd, J = 15.3, 7.6, 1.5 Hz, 1 H), 3.77 (d, J = 6.5 Hz, 1H), 3.39 (t, J = 7.0 Hz, 1H), 2.39 (br, 2H), 1.57 (dd, J = 6.4, 1.0 Hz, 3H).

실시예 3. (3Example 3 (3 SS ,4,4 S,S, 1One EE )-1,5-디페닐-4-(트리틸아미노)-펜트-1-엔-3-올의 제조방법Method for preparing 1,5-diphenyl-4- (tritylamino) -pent-1-en-3-ol

참고예 6에서 얻은 (4S,1E)-1,5-디페닐-4-(트리틸아미노)-펜트-1-엔-3-온을 사용하여 실시예 1과 동일한 방법으로 상기의 표제 화합물 (3S,4S,1E)-1,5-디페닐-4-(트리틸아미노)-펜트-1-엔-3-올 (74%, 거품형 고체)을 얻었다.Using the (4S , 1 E ) -1,5-diphenyl-4- (tritylamino) -pent-1-en-3-one obtained in Reference Example 6 in the same manner as in Example 1 compound (3 S, 4 S, 1 E) -1,5- diphenyl-4- (trityl-amino) pent-1-ene to give the 3-ol (74%, solid foam).

[α]D 25 90.36 (c 1.37, CHCl3);[α] D 25 90.36 (c 1.37, CHCl 3 );

1H NMR (CDCl3) 7.58-6.86 (m, 25 H), 6.53 (dd, J=16.0, 1.5 Hz, 1 H), 5.94 (dd, J=16.0, 4.8 Hz, 1 H), 4.02 (m, 1 H), 2.80 (m, 1 H), 2.53 (dd, J=13.3, 11.6 Hz, 1 H), 2.26 (dd, J=13.3, 4.2 Hz, 1 H). 1 H NMR (CDCl 3 ) 7.58-6.86 (m, 25 H), 6.53 (dd, J = 16.0, 1.5 Hz, 1 H), 5.94 (dd, J = 16.0, 4.8 Hz, 1 H), 4.02 (m , 1 H), 2.80 (m, 1 H), 2.53 (dd, J = 13.3, 11.6 Hz, 1 H), 2.26 (dd, J = 13.3, 4.2 Hz, 1 H).

실시예 4. (4Example 4. (4 S,S, 33 S,S, 1One E)E) -6-메틸-1-페닐-4-(트리틸아미노)-헵트-1-엔-3-올의 제조방법Preparation of -6-methyl-1-phenyl-4- (tritylamino) -hept-1-en-3-ol

참고예 7에서 얻은 (4S, 1E)-6-메틸-1-페닐-4-(트리틸아미노)-헵트-1-엔-3-온을 사용하여 실시예 1과 동일한 방법으로 상기의 표제 화합물 (4S,3S,1E)-6-메틸-1-페닐-4-(트리틸아미노)-헵트-1-엔-3-올 (68%, 무색 결정)을 얻었다.The title compound described above in the same manner as in Example 1 using (4S, 1E) -6-methyl-1-phenyl-4- (tritylamino) -hept-1-en-3-one obtained in Reference Example 7. ( 4S, 3S, 1 E ) -6-methyl-1-phenyl-4- (tritylamino) -hept-1-en-3-ol (68%, colorless crystals) was obtained.

mp 136-138℃; mp 136-138 ° C .;

[α]D 25 85.62 (c 1.35, CHCl3);[α] D 25 85.62 (c 1.35, CHCl 3 );

1H NMR (CDCl3) 7.54-7.17 (m, 20 H), 6.64 (dd, J=15.9, 1.3 Hz, 1 H), 6.16 (dd, J=15.9, 5.5 Hz, 1 H), 4.11 (m, 1 H), 2.67 (dt, J=8.8, 3.9 Hz, 1 H), 2.50 (br, 2 H), 1.46 (m, 1 H), 1.26 (m, 1 H), 0.57 (d, J=6.5 Hz, 3 H), 0.50 (d, J=6.5 Hz, 3 H). 1 H NMR (CDCl 3 ) 7.54-7.17 (m, 20 H), 6.64 (dd, J = 15.9, 1.3 Hz, 1 H), 6.16 (dd, J = 15.9, 5.5 Hz, 1 H), 4.11 (m , 1 H), 2.67 (dt, J = 8.8, 3.9 Hz, 1 H), 2.50 (br, 2 H), 1.46 (m, 1 H), 1.26 (m, 1 H), 0.57 (d, J = 6.5 Hz, 3 H), 0.50 (d, J = 6.5 Hz, 3 H).

실시예 5. (1Example 5 (1 RR ,2,2 S,S, 33 EE )-1-아미노-1,4-디페닐-부트-3-엔-2-올의 제조방법Method for preparing 1-amino-1,4-diphenyl-but-3-en-2-ol

참고예 8에서 얻어진 (1R,3E)-1-아미노-1,4-디페닐-부트-3-엔-2-온 염산염 (0.3 g, 0.9 mmol)을 THF (30 ml)에 가하고 78℃로 냉각하였다. Zn(BH4)2 (0.1 M in THF, 1.8 ml, 1.8 mmol) 용액을 주사기로 적가한 후 5시간 동안 같은 온도에서 교반하였다. 반응액에 물 30 ml을 주의해서 가하고 1N-HCl 용액으로 PH 약 1이 되게 한 후 상온에서 2 시간 교반하였다. n-헥산으로 세척하고 수층을 취하여 1N-NaOH 용액으로 PH 10으로 조절하고 CHCl3으로 3 회 추출하였다. 무수 Na2SO4로 건조하고 감압 증류 후 속성 크로마토그라피로 분리하여 흰색의 고체를 얻었으며 Et2O/n-헥산 (1/3)으로 재결정하여 상기의 표제 화합물 (0.20 g, 75%)를 얻었다.Note obtained in Example 8 (1 R, 3 E) -1- amino-1,4-diphenyl-boot-3-en-2-one hydrochloride (0.3 g, 0.9 mmol) was added to a THF (30 ml) 78 Cooled to C. Zn (BH 4) 2 (0.1 M in THF, 1.8 ml, 1.8 mmol) solution was added dropwise by syringe and stirred at the same temperature for 5 hours. 30 ml of water was carefully added to the reaction solution, and the pH was adjusted to 1 with 1N-HCl solution, followed by stirring at room temperature for 2 hours. Washed with n -hexane, the aqueous layer was taken, adjusted to PH 10 with 1N-NaOH solution and extracted three times with CHCl 3 . After drying over anhydrous Na 2 SO 4 , distillation under reduced pressure, and separated by flash chromatography, a white solid was obtained, and recrystallized with Et 2 O / n -hexane (1/3) to obtain the title compound (0.20 g, 75%). Got it.

mp 95-96℃; mp 95-96 ° C .;

[α]D 25 87.38 (c 0.93, CHCl3);[α] D 25 87.38 (c 0.93, CHCl 3 );

1H NMR (CDCl3) 7.35-7.21 (m, 10 H), 6.62 (d, J=16.0 Hz, 1 H), 6.04 (dd, J=16.0, 6.4 Hz, 1 H), 4.41 (t, J=5.5 Hz, 1 H), 4.08 (d, J=5.5 Hz, 1 H), 2.10 (br s, 3 H); 1 H NMR (CDCl 3 ) 7.35-7.21 (m, 10H), 6.62 (d, J = 16.0 Hz, 1 H), 6.04 (dd, J = 16.0, 6.4 Hz, 1 H), 4.41 (t, J = 5.5 Hz, 1 H), 4.08 (d, J = 5.5 Hz, 1 H), 2.10 (br s, 3 H);

FAB MS m/z : 240 (M+1).FAB MS m / z : 240 (M + l).

실시예 6. (1Example 6. (1 RR ,2,2 S,S, 33 EE )-1-아미노-1-페닐-펜트-3-엔-2-올 염산염의 제조방법Method for preparing 1-1-amino-1-phenyl-pent-3-en-2-ol hydrochloride

참고예 9에서 얻어진 (1R,3E)-1-아미노-1-페닐-펜트-3-엔-3-온 염산염을 출발물질로 실시예 5와 동일한 방법을 사용하여 표제 화합물 (1R,2S,3E)-1-아미노-1-페닐-펜트-3-엔-e-올 염산염 (83%, 무색 결정)을 얻었다.Using ( 1R, 3E ) -1-amino-1-phenyl-pent-3-en-3-one hydrochloride obtained in Reference Example 9 as a starting material using the same method as in Example 5, the title compound ( 1R , 2 S, 3 E ) -1-amino-1-phenyl-pent-3-ene- e -ol hydrochloride (83%, colorless crystals) was obtained.

mp 164.5-165.5℃; mp 164.5-165.5 ° C .;

[α]D 25 +3.40 (c 0.99, MeOH);[α] D 25 +3.40 (c 0.99, MeOH);

1H NMR (CD3OD) 7.46-7.37 (m, 5 H), 5.80 (m, 1 H), 5.22 (ddd, J=15.3, 7.3, 1.7 Hz, 1 H), 4.46 (t, J=4.9 Hz, 1 H), 4.24 (d, J=4.7 Hz, 1 H), 1.63 (dd, J=6.5, 0.8 Hz, 3 H); 1 H NMR (CD 3 OD) 7.46-7.37 (m, 5H), 5.80 (m, 1H), 5.22 (ddd, J = 15.3, 7.3, 1.7 Hz, 1H), 4.46 (t, J = 4.9 Hz, 1H), 4.24 (d, J = 4.7 Hz, 1H), 1.63 (dd, J = 6.5, 0.8 Hz, 3H);

FAB MS m/z : 178 (M+1-HCl).FAB MS m / z : 178 (M + 1-HCl).

실시예 7. (4Example 7. (4 SS ,3, 3 R,R, 1One EE )-4-아미노-1,5-디페닐-펜트-1-엔-3-올 염산염의 제조방법Method for preparing 4-amino-1,5-diphenyl-pent-1-en-3-ol hydrochloride

참고예 10에서 얻어진 (4S,1E)-4-아미노-1,5-디페닐-1-펜트-1-엔-3-온 염산염을 출발물질로 실시예 5와 동일한 방법을 사용하여 표제 화합물 (4S,3R,1E)-4-아미노-1,5-디페닐-펜트-1-엔-3-올 염산염 (78%, 무색 결정)을 얻었다.Using (4 S, 1 E ) -4-amino-1,5-diphenyl-1-pent-1-en-3-one hydrochloride obtained in Reference Example 10 as a starting material using the same method as in Example 5 Compound ( 4S , 3R, 1E ) -4-amino-1,5-diphenyl-pent-1-en-3-ol hydrochloride (78%, colorless crystals) was obtained.

mp 206-207℃; mp 206-207 ° C;

[α]D25 +48.23 (c 0.39, MeOH); [α] D25 +48.23 (c 0.39, MeOH);

1H NMR (CD3OD) 7.44-7.23 (m, 10 H), 6.75 (d, J=15.9 Hz, 1 H), 6.28 (dd, J=15.9, 6.4 Hz, 1 H), 4.48 (m, 1 H), 3.63 (m, 1 H), 3.03 (dd, J=14.4, 8.3 Hz, 1 H), 2.87 (dd, J=14.4, 8.3 Hz, 1 H); 1 H NMR (CD 3 OD) 7.44-7.23 (m, 10H), 6.75 (d, J = 15.9 Hz, 1 H), 6.28 (dd, J = 15.9, 6.4 Hz, 1 H), 4.48 (m, 1 H), 3.63 (m, 1 H), 3.03 (dd, J = 14.4, 8.3 Hz, 1 H), 2.87 (dd, J = 14.4, 8.3 Hz, 1 H);

FAB MS m/z: 254 (M+1-HCl).FAB MS m / z : 254 (M + 1-HCl).

실시예 8. (3Example 8 (3 RR ,4,4 S,S, 1One EE )-4-아미노-6-메틸-1-페닐-헵트-1-엔-3-올 염산염의 제조방법Method for preparing 4-amino-6-methyl-1-phenyl-hept-1-en-3-ol hydrochloride

참고예 11에서 얻어진 (4S,1E)-4-아미노-6-메틸-1-페닐-헵트-1-엔-3-온 염산염을 출발물질로 실시예 5와 동일한 방법을 사용하여 표제 화합물 (3R,4S,1E)-4-아미노-6-메틸-1-페닐-헵트-1-엔-3-올 염산염 (88%, 무색 결정)을 얻었다.( 4S, 1 E ) -4-amino-6-methyl-1-phenyl-hept-1-en-3-one hydrochloride obtained in Reference Example 11, using the same method as in Example 5 as a starting material, the title compound. ( 3R , 4S, 1E ) -4-Amino-6-methyl-1-phenyl-hept-1-en-3-ol hydrochloride (88%, colorless crystals) was obtained.

mp 83-84℃;mp 83-84 ° C .;

[α]D 25 3.30 (c 1.24, MeOH);[α] D 25 3.30 (c 1.24, MeOH);

1H NMR (CD3OD) 7.46-7.21 (m, 5 H), 6.77 (d, J=15.9 Hz, 1 H), 6.25 (dd, J=15.9, 6.3 Hz, 1 H), 4.50 (m, 1 H), 3.40 (m, 1 H), 1.75 (m, 1 H), 1.49 (t, J=7.3 Hz, 2 H), 0.98 (d, J=3.3 Hz, 3 H), 0.94 (d, J=3.3 Hz, 3 H); 1 H NMR (CD 3 OD) 7.46-7.21 (m, 5H), 6.77 (d, J = 15.9 Hz, 1 H), 6.25 (dd, J = 15.9, 6.3 Hz, 1 H), 4.50 (m, 1 H), 3.40 (m, 1 H), 1.75 (m, 1 H), 1.49 (t, J = 7.3 Hz, 2 H), 0.98 (d, J = 3.3 Hz, 3 H), 0.94 (d, J = 3.3 Hz, 3 H);

FAB MS m/z :220 (M+1-HCl).FAB MS m / z : 220 (M + 1-HCl).

실시예 9. (1Example 9. (1 RR ,2,2 R,R, 33 EE )-1-아미노-1,4-디페닐-부트-3-엔-2-올의 제조방법Method for preparing 1-amino-1,4-diphenyl-but-3-en-2-ol

실시예 1에서 얻어진 (1R,2R,3E)-1,4-디페닐-1-(트리틸아미노)-부트-3-엔-2-올 (70 mg)을 THF (3 ml)와 1N-HCl (1 ml)에 가하고 30분 상온에서 교반하였다. 포화 NaHCO3 용액으로 알카리 성으로 만들고 CHCl3로 추출하였다. 유기층을 건조하고 Et2O로 재결정하여 상기의 표제 화합물 (1R,2R,3E)-1-아미노-1,4-디페닐-부트-3-엔-2-올 (48 mg, 70%)을 백색의 고체로 얻었다.Example 1 obtained in the (1 R, 2 R, 3 E) -1,4- diphenyl-1- (trityl-amino) boot-3-en-2-ol (70 mg) with THF (3 ml) And 1N-HCl (1 ml) were added and stirred at room temperature for 30 minutes. Alkaline with saturated NaHCO 3 solution and extracted with CHCl 3 . The organic layer was dried and recrystallized with Et 2 O to give the title compound (1 R , 2 R, 3 E ) -1-amino-1,4-diphenyl-but-3-en-2-ol (48 mg, 70 %) Was obtained as a white solid.

mp 125-126℃; mp 125-126 ° C .;

[α]D 25 +96.79 (c 1.0, CHCl3);[α] D 25 +96.79 (c 1.0, CHCl 3 );

IR (NaCl film) 3361, 3028, 1448 cm-1;IR (NaCl film) 3361, 3028, 1448 cm −1 ;

1H NMR (CDCl3) 7.36-7.19 (m, 10 H), 6.57 (dd, J=15.9, 1.0 Hz, 1 H), 6.08 (dd, J=15.9, 5.5 Hz, 1 H), 4.30 (dt, J=6.7, 1.2 Hz, 1 H), 3.85 (d, J= 6.7 Hz, 1 H), 2.36 (br s, 3 H); 1 H NMR (CDCl 3 ) 7.36-7.19 (m, 10H), 6.57 (dd, J = 15.9, 1.0 Hz, 1H), 6.08 (dd, J = 15.9, 5.5 Hz, 1H), 4.30 (dt , J = 6.7, 1.2 Hz, 1 H), 3.85 (d, J = 6.7 Hz, 1 H), 2.36 (br s, 3 H);

FAB MS m/z : 240 (M+1).FAB MS m / z : 240 (M + l).

실시예 10. (1Example 10. (1 RR ,2,2 RR )-1-(벤조일아미노)-2-() -1- (benzoylamino) -2- ( t-t- 부틸디메틸실릴옥시)-1,4-디페닐-부트-3-엔의 제조방법Method for preparing Butyldimethylsilyloxy) -1,4-diphenyl-but-3-ene

실시예 9에서 얻어진 (1R,2R,3E)-1-아미노-1,4-디페닐-부트-3-엔-2-올 (55 mg, 0.23 mmol)와 Et3N (21 mg, 0.46 mmol)을 CH2Cl2 (5 ml) 넣고 0℃로 냉각하였다. PhCOCl (48.3 mg, 0.35 mmol)를 가하고 상온에서 하루 밤 교반하였다. 감압 증류하여 용매를 제거하고 MeOH (3 ml)과 묽은 1N-K2CO3 수용액 (1 ml)을 가하고 50℃ 전후에서 0.5 시간 교반하여 O-벤조일레이션된 화합물을 가수분해 하였다. 묽은 염산으로 PH 2-3으로 조정하고 EtOAc로 추출 후 감압 증류하여 N-Bz으로 보호된 화합물을 정량적으로 흰색의 고체로 얻었다. 필요하면 CH2Cl2/n-헥산 (10/1)으로 재결정할 수 있으며 정제하지 않고 다음 반응을 진행하였다{mp 178-179℃; [α]D 25 1.89 (c 1.09, CHCl3)}. 이 화합물에 디메틸포름아미드(DMF) (1 ml)를 가하여 녹이고 이미다졸 (31 mg, 0.46 mmol)과 4-디메틸아미노피리딘(DMAP)(촉매량)과 TBDMSCl (52mg, 0.35mmol)를 각각 가하고 상온에서 4 시간 교반하였다. 물과 Et2O를 넣고 추출한 후 유기층을 건조, 감압 증류 하였다. 속성 크로마토그래피 (EtOAc/n-헥산=1/6, rf=0.20)로 분리 후 50%-EtOH로 재결정하여 상기의 표제 화합물 (1R,2R)-1-(벤조일아미노)-2-(t-부틸디메틸실릴옥시)-1,4-디페닐-부트-3-엔 (93 mg, 88%)을 흰색의 결정으로 얻었다.Embodiments obtained in Example 9 (1 R, 2 R, 3 E) -1- amino-1,4-diphenyl-boot-3-en-2-ol (55 mg, 0.23 mmol) and Et3N (21 mg, 0.46 mmol) were added CH 2 Cl 2 (5 ml) and cooled to 0 ° C. PhCOCl (48.3 mg, 0.35 mmol) was added and stirred at room temperature overnight. The solvent was removed by distillation under reduced pressure, MeOH (3 ml) and dilute 1N-K 2 CO 3 aqueous solution (1 ml) were added, and the O -benzoylated compound was hydrolyzed by stirring for about 0.5 hours at 50 ° C. The mixture was adjusted to PH 2-3 with dilute hydrochloric acid, extracted with EtOAc, and distilled under reduced pressure to obtain a compound protected with N- Bz as a white solid. If necessary, it could be recrystallized from CH 2 Cl 2 / n -hexane (10/1), and the following reaction was carried out without purification {mp 178-179 ° C; [α] D 25 1.89 (c 1.09, CHCl 3 )}. To this compound was dissolved dimethylformamide (DMF) (1 ml), imidazole (31 mg, 0.46 mmol), 4-dimethylaminopyridine (DMAP) (catalyst amount) and TBDMSCl (52 mg, 0.35 mmol), respectively, were added at room temperature. Stir for 4 hours. Water and Et 2 O were added and extracted, and the organic layer was dried and distilled under reduced pressure. Separation by flash chromatography (EtOAc / n -hexane = 1/6, rf = 0.20) and recrystallization from 50% -EtOH to give the title compound (1 R , 2 R ) -1- (benzoylamino) -2- ( t -butyldimethylsilyloxy) -1,4-diphenyl-but-3-ene (93 mg, 88%) was obtained as white crystals.

mp 117-119℃; mp 117-119 ° C;

[α]D 25 14.56 (c 0.89, CHCl3);[α] D 25 14.56 (c 0.89, CHCl 3 );

IR (NaCl film) 2929, 1656, 1484 cm-1;IR (NaCl film) 2929, 1656, 1484 cm −1 ;

1H NMR (CDCl3) 7.81-7.22 (m, 15 H), 7.15 (d, J=8.3 Hz, 1 H, NH), 6.66 (d, J=15.9 Hz, 1 H), 6.30 (dd, J=15.9, 5,9 Hz, 1 H), 5.30 (dd, J=8.3, 1.8 Hz, 1 H), 4.64 (m, 1 H), 0.87 (s, 9 H), -0.11 (s, 3 H), -0.38 (s, 3 H); 1 H NMR (CDCl 3 ) 7.81-7.22 (m, 15 H), 7.15 (d, J = 8.3 Hz, 1 H, NH), 6.66 (d, J = 15.9 Hz, 1 H), 6.30 (dd, J = 15.9, 5,9 Hz, 1 H), 5.30 (dd, J = 8.3, 1.8 Hz, 1 H), 4.64 (m, 1 H), 0.87 (s, 9 H), -0.11 (s, 3 H ), -0.38 (s, 3H);

FAB MS m/z : 458 (M+1).FAB MS m / z : 458 (M + l).

실시예 11. (2Example 11. (2 SS ,3, 3 RR )-3-벤조일아미노-2-() -3-benzoylamino-2- ( tt -부틸디메틸실릴옥시)-3-페닐프로피오닉산 메틸에스테르의 제조방법-Butyldimethylsilyloxy) -3-phenylpropionic acid methyl ester

CH2Cl2 (15 ml)에 화합물 실시예 10에서 얻어진 (1R, 2R)-1-(벤조일아미노)-2-(t-부틸디메틸실릴옥시)-1,4-디페닐-부트-3-엔 (100 mg, 0.22 mmol)을 가한 후 78℃로 냉각하였다. 2.5M-methanolic NaOH 용액 (0.5 ml)을 넣고 O3를 주입하면서 2 시간 후 반응을 종결하였다 (푸른색). 물을 가하고 추출 후 유기층을 건조, 감압 증류하였다. 속성 크로마토그래피 (EtOAc/n-헥산=1/8, rf=0.18)로 분리하여 무색의 시럽으로 상기의 표제 화합물 (2S,3R)-3-벤조일아미노-2-(t-부틸디메틸실릴옥시)-3-페닐프로피오닉산 메틸에스테르 (71 mg, 77%)를 얻었다.CH2Cl2 (1 R, 2 R) obtained in the Example 10 compound in (15 ml) -1- (benzoylamino) -2- (t-butyldimethylsilyloxy) -1,4-diphenyl-3-en Boot (100 mg, 0.22 mmol) was added and then cooled to 78 ° C. 2.5 M-methanolic NaOH solution (0.5 ml) was added and the reaction was terminated after 2 hours while injecting O 3 (blue). Water was added, and after extraction, the organic layer was dried and distilled under reduced pressure. Flash chromatography (EtOAc / n - hexane = 1/8, rf = 0.18 ) separated by a colorless syrup of the title compound (2 S, 3 R) -3- benzoylamino -2- (t - butyldimethylsilyl Oxy) -3-phenylpropionic acid methyl ester (71 mg, 77%) was obtained.

[α]D 25 +45.66 (c 2.10, CHCl3);[α] D 25 +45.66 (c 2.10, CHCl 3 );

1H NMR (CDCl3) 7.81-7.22 (m, 11 H), 5.59 (dd, J=8.5, 1.7 Hz, 1 H), 4.50 (d, J=1.7 Hz, 1 H), 3.74 (s, 3 H), 0.77 (s, 9 H), -0.11 (s, 3 H), -0.34 (s, 3 H). 1 H NMR (CDCl 3 ) 7.81-7.22 (m, 11H), 5.59 (dd, J = 8.5, 1.7 Hz, 1H), 4.50 (d, J = 1.7 Hz, 1H), 3.74 (s, 3 H), 0.77 (s, 9 H), -0.11 (s, 3 H), -0.34 (s, 3 H).

실시예 12. (2Example 12. (2 SS ,3, 3 RR )-3-벤조일아미노-2-히드록시-3-페닐 프로피오닉산 메틸에스테르의 제조방법Method for preparing 3-benzoylamino-2-hydroxy-3-phenyl propionic acid methyl ester

THF (5 ml)에 실시예 11에서 얻어진 화합물 (2S, 3R)-3-벤조일아미노-2-(t-부틸디메틸실릴옥시)-3-페닐프로피오닉산 메틸에스테르 (37 mg, 0.089 mmol)를 넣고 빙욕조로 냉각하고 테트라부틸암모늄플루오라이드(TBAF)(1.0 M in THF, 0.12 ml, 0.12 mmol)를 가하였다. 같은 온도에서 1.5 시간 교반하고 물과 EtOAc를 넣은 후 염산으로 수층을 pH 2-3으로 조정하고 추출하였다. 유기층을 건조, 감압증류하면 고체가 석출되며 EtOAc/n-헥산=1/3의 혼합 용매로 재결정하여 상기 표제 화합물 (2S,3R)-3-벤조일아미노-2-히드록시-3-페닐프로피오닉산 메틸에스테르 (25 mg, 93%)을 흰색의 바늘형 결정으로 얻었다.The compound obtained in Example 11 in THF (5 ml) (2 S, 3 R) -3-benzoylamino -2- (t - butyldimethylsilyloxy) -3-phenyl-propionic acid methyl ester (37 mg, 0.089 mmol ), Cooled in an ice bath, and tetrabutylammonium fluoride (TBAF) (1.0 M in THF, 0.12 ml, 0.12 mmol) was added thereto. After stirring at the same temperature for 1.5 hours, water and EtOAc were added, and the aqueous layer was adjusted to pH 2-3 with hydrochloric acid and extracted. The organic layer was dried and evaporated under reduced pressure to precipitate a solid, which was recrystallized with a mixed solvent of EtOAc / n -hexane = 1/3. ( 2S , 3R ) -3-benzoylamino-2-hydroxy-3-phenylpropionic acid methyl ester (25 mg, 93%) was obtained as white needle crystals.

mp 181-183℃; mp 181-183 ° C;

[α]D 25 +47.2 (c 0.35, MeOH);[α] D 25 +47.2 (c 0.35, MeOH);

[α]D 25 +49.1 (c 1.01, MeOH);[α] D 25 +49.1 (c 1.01, MeOH);

1H NMR (CDCl3) 7.76-7.28 (m, 10 H), 7.00 (d, J=9.0 Hz, 1 H), 5.72 (dd, J=9.0, 1.9 Hz, 1 H), 4.61 (d, J=1.9 Hz, 1 H), 3.82 (s, 3 H), 3.33 (br, 1 H). 1 H NMR (CDCl 3 ) 7.76-7.28 (m, 10H), 7.00 (d, J = 9.0 Hz, 1H), 5.72 (dd, J = 9.0, 1.9 Hz, 1H), 4.61 (d, J = 1.9 Hz, 1 H), 3.82 (s, 3 H), 3.33 (br, 1 H).

실시예 13. (2Example 13. (2 RR ,3, 3 RR )-3-벤조일아미노-2-히드록시-3-페닐프로피오닉산 메틸에스테르의 제조방법Method of Preparation) -3-benzoylamino-2-hydroxy-3-phenylpropionic acid methyl ester

실시예 5에서 얻어진 (1R,2S,3E)-1-아미노-1,4-디페닐-부트-3-엔-2-올에서 출발하여 실시예 12의 합성과 동일한 경로로 상기의 표제 화합물을 제조하였다.Embodiments obtained in Example 5 (1 R, 2 S, 3 E) -1- amino-1,4-diphenyl-boot-3-en-2-ol in the same path for the synthesis of Example 12, starting of the The title compound was prepared.

mp 153-154℃; mp 153-154 ° C;

[α]D 25 +24.08 (c 0.96, CHCl3 );[α] D 25 +24.08 (c 0.96, CHC1 3 );

1H NMR (CDCl3) 7.82-7.26 (m, 11 H, NH 포함), 5.60 (dd, J=8.6, 3.6 Hz, 1 H), 4.70 (d, J=3.6 Hz, 1 H), 3.72 (s, 3 H). 1 H NMR (CDCl 3 ) 7.82-7.26 (m, 11H, including NH), 5.60 (dd, J = 8.6, 3.6 Hz, 1H), 4.70 (d, J = 3.6 Hz, 1H), 3.72 ( s, 3 H).

13C NMR (CDCl3) 172.9, 167.4, 137.2, 134.7, 132.4, 129.3, 129.1, 128.2, 127.8, 73.7, 56.2, 53.4. 13 C NMR (CDCl 3 ) 172.9, 167.4, 137.2, 134.7, 132.4, 129.3, 129.1, 128.2, 127.8, 73.7, 56.2, 53.4.

실시예 14. (3Example 14 (3 RR )-2-옥소-3-페닐-3-(트리틸아미노)-프로피오닉산 메틸에스테르의 제조방법) Oxo-3-phenyl-3- (tritylamino) -propionic acid methyl ester

CH2Cl2 (30 ml)에 화합물 참고예 4에서 얻어진 (1R,3E)-1,4-디페닐-1-(트리틸아미노)-부트-3-엔-2-온 (600 mg, 1.25 mmol)을 가한 후 78℃로 냉각하였다. 1M-methanolic NaOH 용액 (6 ml)을 넣고 O3를 주입하면서 3 시간 후 반응을 종결하였다 (푸른색). 물을 넣고 포화 시트르산 용액 (3 ml)을 가한 후 추출하였다. 유기층을 건조, 감압 증류 후 속성 크로마토그래피 (EtOAc/n-헥산=1/3, rf=0.53)로 분리하였다. 잠시 방치 후 고체화되며 80%-EtOH로 재결정하여 연노랑색 결정으로 표제 화합물 (3R)-2-옥소-3-페닐-3-(트리틸아미노)-프로피오닉산 메틸에스테르 (408 mg, 75%)을 얻었다.CH 2 Cl 2 (30 ml) obtained in compound Reference Example 4 (1 R, 3 E ) -1,4-diphenyl-1- (tritylamino) -but-3-en-2-one (600 mg, 1.25 mmol) was added and then cooled to 78 ° C. 1M-methanolic NaOH solution (6 ml) was added and the reaction was terminated after 3 hours while injecting O 3 (blue). Water was added and saturated citric acid solution (3 ml) was added and extracted. The organic layer was dried, dried under reduced pressure, and separated by flash chromatography (EtOAc / n -hexane = 1/3, rf = 0.53). After brief standing it solidified and recrystallized with 80% -EtOH to give pale yellow crystals as the title compound ( 3R ) -2-oxo-3-phenyl-3- (tritylamino) -propionic acid methyl ester (408 mg, 75% )

mp 131-132℃; mp 131-132 ° C;

[α]D 25 -252.59 (c 1.04, CHCl3);[α] D 25 -252.59 (c 1.04, CHC1 3 );

IR (NaCl film) 1730 (CO) cm-1;IR (NaCl film) 1730 (CO) cm −1 ;

1H NMR (CDCl3) 7.55-7.17 (m, 20 H), 5.34 (s, 1 H), 3.75 (br, 1 H), 3.57 (s, 3 H). 1 H NMR (CDCl 3 ) 7.55-7.17 (m, 20H), 5.34 (s, 1H), 3.75 (br, 1H), 3.57 (s, 3H).

실시예 15 (3Example 15 (3 SS )-2-옥소-4-페닐-3-(트리틸아미노)-부티릭산 메틸에스테르의 제조방법Method for preparing 2-oxo-4-phenyl-3- (tritylamino) -butyric acid methyl ester

참고예 6에서 제조된 (4S,1E)-1,5-디페닐-4-(트리틸아미노)-펜트-1-엔-3-온을 출발물질로 사용하여 실시예 14와 동일한 방법으로 표제 화합물 (78%, 연노랑 결정)을 얻었다.The same method as Example 14 using (4S , 1E ) -1,5-diphenyl-4- (tritylamino) -pent-1-en-3-one prepared in Reference Example 6 as a starting material. The title compound (78%, light yellow crystals) was obtained.

mp 108-109℃; mp 108-109 ° C .;

[α]D25 +117.01 (c 1.01, CHCl3);[α] D25 +117.01 (c 1.01, CHCl 3 );

IR (NaCl film) 1729 (CO) cm-1;IR (NaCl film) 1729 (CO) cm −1 ;

1H NMR (CDCl3) 7.35-7.11 (m, 20 H), 4.41 (dd, J=7.1, 5.8 Hz, 1 H), 3.60 (s, 3 H), 2.95 (dd, J=13.3, 5.4 Hz, 2 H, NH 포함), 2.71 (dd, J=13.3, 5.4 Hz, 1 H); 1 H NMR (CDCl 3 ) 7.35-7.11 (m, 20H), 4.41 (dd, J = 7.1, 5.8 Hz, 1H), 3.60 (s, 3H), 2.95 (dd, J = 13.3, 5.4 Hz , 2 H, NH), 2.71 (dd, J = 13.3, 5.4 Hz, 1 H);

FAB MS m/z :450 (M+1).FAB MS m / z : 450 (M + l).

실시예 16. (3Example 16. (3 SS )-5-메틸-2-옥소-3-(트리틸아미노)-헥사노익산 메틸에스테르의 제조방법(Method) -5-methyl-2-oxo-3- (tritylamino) -hexanoic acid methyl ester

참고예 7에서 제조된 (4S,1E)-6-메틸-1-페닐-4-(트리틸아미노)-헵트-1-엔-3-온을 출발물질로 사용하여 실시예 14와 동일한 방법으로 표제 화합물 (80%, 노랑 시럽)을 얻었다.In the same manner as in Example 14, using (4S, 1E) -6-methyl-1-phenyl-4- (tritylamino) -hept-1-en-3-one prepared in Reference Example 7 as a starting material. The title compound (80%, yellow syrup) was obtained.

[α]D 25 +77.47 (c 0.52, CHCl3);[α] D 25 +77.47 (c 0.52, CHCl 3 );

IR (NaCl film) 1729 (CO) cm-1;IR (NaCl film) 1729 (CO) cm −1 ;

1H NMR (CDCl3) 7.51-7.13 (m, 15 H), 4.16 (t, J=6.6 Hz, 1 H), 3.65 (s, 3 H), 2.78 (br, 1H), 1.94 (m, 1 H), 1.40 (t, J=6.7 Hz, 2 H), 0.93 (t, J=6.7 Hz, 6 H); 1 H NMR (CDCl 3 ) 7.51-7.13 (m, 15 H), 4.16 (t, J = 6.6 Hz, 1 H), 3.65 (s, 3 H), 2.78 (br, 1H), 1.94 (m, 1 H), 1.40 (t, J = 6.7 Hz, 2H), 0.93 (t, J = 6.7 Hz, 6H);

FAB MS m/z : 416 (M+1).FAB MS m / z : 416 (M + l).

실시예 17. (2Example 17. (2 RR ,3, 3 RR )-3-아미노-2-히드록시-3-페닐-프로피오닉산 메틸에스테르의 제조방법A method for preparing methyl-3-amino-2-hydroxy-3-phenyl-propionic acid methyl ester

실시예 14에서 얻어진 α-케토 에스테르 (3R)-2-옥소-3-페닐-3-(트리틸아미노)-프로피오닉산 메틸에스테르 (200 mg, 0.46 mmol)를 MeOH (5 ml)에 넣고 conc-HCl (0.13 ml, 1.6 mmol)를 가하였다. 상온에서 40 분 교반하고 n-헥산 (23 ml)으로 세척하였다. MeOH 층을 취하여 감압 증류 후 다시 MeOH ( 5 ml)를 가하고 감압 증류 하였다. 얻어진 시럽형의 생성물에 포함된 물과 과량의 HCl을 고진공에서 여러 시간 휘발시켜 흰색의 반 고체(semi solid)로서 트리틸기가 탈보호된 에논 염산염을 정량적으로 얻었다. 잔사에 MeOH (5 ml)을 넣어 녹이고 20℃로 냉각 후 NaBH4 (52 mg, 1.38 mmol)을 3 회에 나누어 가하였다. 같은 온도에서 1 시간 교반하고 물 (5 ml)을 넣은 후 감압 증류하여 대부분의 MeOH를 제거하였다. CHCl3으로 추출 (415 ml)하고 유기층을 건조, 감압 증류하면 결정이 얻어지며 EtOAc/n-헥산 (1/3)의 혼합 용매로 재결정하여 흰색 결정으로 상기 표제 화합물 (2R,3R)-3-아미노-2-히드록시-3-페닐-프로피오닉산 메틸에스테르 (66 mg, 73%)를 얻었다.Α-keto ester (3R) -2-oxo-3-phenyl-3- (tritylamino) -propionic acid methyl ester (200 mg, 0.46 mmol) obtained in Example 14 was added to MeOH (5 ml) and conc -HCl (0.13 ml, 1.6 mmol) was added. Stir at room temperature for 40 minutes and wash with n-hexane (23 ml). The MeOH layer was taken, distillation under reduced pressure, MeOH (5 ml) was added again, and distillation under reduced pressure. Water and excess HCl contained in the obtained syrup-like product were volatilized for several hours under high vacuum to quantitatively obtain enon hydrochloride having a trityl group deprotected as a white semi solid. MeOH (5 ml) was added to the residue, and the mixture was cooled to 20 ° C and NaBH 4 (52 mg, 1.38 mmol) was added in three portions. After stirring for 1 hour at the same temperature, water (5 ml) was added and distillation under reduced pressure to remove most of the MeOH. Extraction with CHCl 3 (415 ml), drying and drying the organic layer under reduced pressure yielded a crystal, which was recrystallized with a mixed solvent of EtOAc / n-hexane (1/3) to obtain the title compound (2R, 3R) -3- as white crystals. Amino-2-hydroxy-3-phenyl-propionic acid methyl ester (66 mg, 73%) was obtained.

mp 84-85℃; mp 84-85 ° C .;

[α]D 25 +31.27 (c 0.56, CHCl3);[α] D 25 +31.27 (c 0.56, CHCl 3 );

1H NMR (CDCl3) 7.30-7.24 (m, 5 H), 4.44 (d, J=4.1 Hz, 1 H), 4.29 (d, J=4.1 Hz, 1 H), 3.63 (s, 3 H), 2.20 (br s, 3 H). 1 H NMR (CDCl 3 ) 7.30-7.24 (m, 5H), 4.44 (d, J = 4.1 Hz, 1H), 4.29 (d, J = 4.1 Hz, 1H), 3.63 (s, 3H) , 2.20 (br s, 3 H).

염산염: Hydrochloride:

mp 172-174℃; mp 172-174 ° C .;

[α]D 25 +14.6(c 0.99, MeOH).[α] D 25 +14.6 (c 0.99, MeOH).

실시예 18. (2Example 18. (2 SS ,3, 3 SS )-3-아미노-2-히드록시-3-페닐-부티릭산 메틸에스테르의 제조방법A method for preparing methyl-3-amino-2-hydroxy-3-phenyl-butyric acid methyl ester

실시예 15에서 얻어진 (3S)-2-옥소-4-페닐-3-(트리틸아미노)-부티릭산 메틸에스테르를 출발물질로 사용하여 실시예 17과 동일한 방법으로 표제 화합물을 얻었다 (83%, 연노랑색 무정형 고체).Using the ( 3S ) -2-oxo-4-phenyl-3- (tritylamino) -butyric acid methyl ester obtained in Example 15 as a starting material, the title compound was obtained in the same manner as in Example 17 (83% , Light yellow amorphous solid).

[α]D 25 +19.3 (c 1.03, 1N-HCl);[α] D 25 +19.3 (c 1.03, 1N-HCl);

1H NMR (CDCl3) 7.33-7.18 (m, 5 H), 4.24 (d, J=3.7 Hz, 1 H), 3.75 (s, 3 H), 3.35 (m, 1 H), 2.81 (dd, J=13.6, 4.6 Hz, 1 H), 2.59 (dd, J= 13.6, 9.4 Hz, 1 H), 2.34 (br, 3 H). 129.2, 127.1. 1 H NMR (CDCl 3 ) 7.33-7.18 (m, 5H), 4.24 (d, J = 3.7 Hz, 1H), 3.75 (s, 3H), 3.35 (m, 1H), 2.81 (dd, J = 13.6, 4.6 Hz, 1 H), 2.59 (dd, J = 13.6, 9.4 Hz, 1 H), 2.34 (br, 3 H). 129.2, 127.1.

이 화합물을 염산으로 처리하면 (2S, 3S)-3-아미노-2-히드록시-3-페닐-부티릭산 메틸에스테르 염산염의 형태로 얻을 수가 있다 (무색 결정).Treatment of this compound with HCl (2S, 3 S) -3-amino-2-hydroxy-3-phenyl-butyric acid can be obtained in the form of the methyl ester hydrochloride (colorless crystals).

염산염: Hydrochloride:

mp 147-148.5℃; mp 147-148.5 ° C .;

[α]D 25 +13.81 (c 0.70, MeOH).[a] D 25 +13.81 (c 0.70, MeOH).

실시예 19. (2Example 19. (2 SS ,3, 3 SS )-3-아미노-2-히드록시-3-메틸-헥사노익산 메틸에스테르의 제조방법A method for preparing methyl-3-amino-2-hydroxy-3-methyl-hexanoic acid methyl ester

실시예 16에서 얻어진 (3S)-5-메틸-2-옥소-3-(트리틸아미노)-헥사노익산 메틸에스테르를 출발물질로 사용하여 실시예 17과 동일한 방법으로 표제 화합물을 얻었다 (80%, 무색 결정).Using the ( 3S ) -5-methyl-2-oxo-3- (tritylamino) -hexanoic acid methyl ester obtained in Example 16 as a starting material, the title compound was obtained in the same manner as in Example 17 (80 %, Colorless crystals).

mp 48-49℃ (진공에서 승화성이 있음); mp 48-49 ° C. (sublimable in vacuum);

[α]D 25 +15.06 (c 0.79, CHCl3);[α] D 25 +15.06 (c 0.79, CHCl 3 );

1H NMR (CD3OD) 4.16 (d, J=3.9 Hz, 1 H), 3.76 (s, 3 H), 4.16 (d, J=3.9 Hz, 1 H), 3.76 (s, 3 H), 3.12 (dt, J=9.3, 4.1 Hz, 1 H), 1.60 (m, 1H), 1.34 (m, 1 H), 1.18 (m, 1 H), 0.95 (d, J=6.6 Hz, 3 H), 0.89 (d, J=6.6 Hz, 3 H). 1 H NMR (CD 3 OD) 4.16 (d, J = 3.9 Hz, 1H), 3.76 (s, 3H), 4.16 (d, J = 3.9 Hz, 1H), 3.76 (s, 3H), 3.12 (dt, J = 9.3, 4.1 Hz, 1H), 1.60 (m, 1H), 1.34 (m, 1H), 1.18 (m, 1H), 0.95 (d, J = 6.6 Hz, 3H) , 0.89 (d, J = 6.6 Hz, 3H).

본 발명에 따른 방법을 사용하면 하나의 출발물질로부터 광학 활성을 갖는 두가지 β-아미노-α-히드록시 카르본산을 높은 입체 선택성으로 얻을 수 있다. 즉 아미노기의 보호기 종류를 달리함으로써 입체조절에 의한 환원 반응과 가교결합에 의한 환원 반응을 선택적으로 수행하여 syn과 anti 이성질체를 목적하는 바에 따라 얻을 수 있는 장점을 가지며 또한 반응 단계가 용이하고 수율이 우수하여 경제성이 매우 뛰어나다.Using the process according to the invention, two β-amino-α-hydroxy carboxylic acids with optical activity can be obtained with high stereoselectivity from one starting material. That is, by changing the type of protecting group of the amino group, the reduction reaction by stereoregulation and the reduction reaction by crosslinking are selectively performed to obtain syn and anti isomers as desired, and the reaction step is easy and the yield is excellent. It is very economical.

Claims (12)

하기 화학식 2의 화합물의 산화반응에 의하여 화학식 1의 β-아미노-α-히드록시 카르본산 및 그 유도체를 제조하는 것을 특징으로 하는 방법:A method of preparing β-amino-α-hydroxy carboxylic acid of Formula 1 and its derivatives by oxidation of a compound of Formula 2: <화학식 1><Formula 1> <화학식2><Formula 2> 상기 식중, n은 0 또는 1이고,Wherein n is 0 or 1, R1은 수소, C1-C8의 알킬기, 페닐기, 또는 벤질기이고,R 1 is hydrogen, a C1-C8 alkyl group, a phenyl group, or a benzyl group, R2는 수소 또는 히드록시기의 보호기이고,R 2 is a protecting group of hydrogen or a hydroxy group, R3는 수소 또는 아민기의 보호기이고,R 3 is a protecting group of hydrogen or an amine group, R4는 C1-C20의 알킬기, C3-C20의 사이클로알킬기, 페닐기 또는 벤질기이며,R 4 is a C1-C20 alkyl group, a C3-C20 cycloalkyl group, a phenyl group or a benzyl group, R5는 수소, C1-C10의 알킬기 또는 페닐기이며,R 5 is hydrogen, a C1-C10 alkyl group or a phenyl group, X는 CH3COO, HCOO, HO2CCH(OH)CH(OH)COO, CH3SO3, CF3 CH3COO, CH3C6H5SO3, Cl, HSO4, 또는 H2PO4이고,X is CH 3 COO, HCOO, HO 2 CCH (OH) CH (OH) COO, CH 3 SO 3 , CF 3 CH 3 COO, CH 3 C 6 H 5 SO 3 , Cl, HSO 4 , or H 2 PO 4 ego, *는 키랄탄소를 의미한다.* Means chiral carbon. 제1항에 있어서, 상기 화학식 2의 화합물은 하기 화학식 4의 화합물을 환원하여 합성되는 것을 특징으로 하는 방법:The method of claim 1, wherein the compound of Formula 2 is synthesized by reducing the compound of Formula 4. <화학식 4><Formula 4> 상기 식중 R3, R4, 및 R5는 청구항 제1항에서 정의한 바와 같다.Wherein R 3 , R 4 , and R 5 are as defined in claim 1. 하기 화학식 3의 화합물의 환원반응에 의하여 화학식 1의 β-아미노-α-히드록시 카르본산 및 그 유도체를 제조하는 것을 특징으로 하는 방법:To prepare a β-amino-α-hydroxy carboxylic acid and its derivatives of the formula (1) by the reduction of the compound of formula (3): <화학식 1><Formula 1> <화학식3><Formula 3> 상기 식중, n은 0 또는 1이고,Wherein n is 0 or 1, R1은 수소, C1-C8의 알킬기, 페닐기 또는 벤질기이고,R 1 is hydrogen, a C1-C8 alkyl group, a phenyl group or a benzyl group, R2는 수소 또는 히드록시기의 보호기이고,R 2 is a protecting group of hydrogen or a hydroxy group, R3는 수소 또는 아민기의 보호기이고,R 3 is a protecting group of hydrogen or an amine group, R4는 C1-C20의 알킬기, C3-C20의 사이클로알킬기, 페닐기 또는 벤질기이며,R 4 is a C1-C20 alkyl group, a C3-C20 cycloalkyl group, a phenyl group or a benzyl group, R5는 수소, C1-C10의 알킬기 또는 페닐기이며,R 5 is hydrogen, a C1-C10 alkyl group or a phenyl group, X는 CH3COO, HCOO, HO2CCH(OH)CH(OH)COO, CH3SO3, CF3 CH3COO, CH3C6H5SO3, Cl, HSO4, 또는 H2PO4이고,X is CH 3 COO, HCOO, HO 2 CCH (OH) CH (OH) COO, CH 3 SO 3 , CF 3 CH 3 COO, CH 3 C 6 H 5 SO 3 , Cl, HSO 4 , or H 2 PO 4 ego, *는 키랄탄소를 의미한다.* Means chiral carbon. 제3항에 있어서, 상기 화학식 3의 화합물은 화학식 4의 화합물을 산화하여 합성되는 것을 특징으로 하는 방법:The method of claim 3, wherein the compound of Formula 3 is synthesized by oxidizing the compound of Formula 4. <화학식 4><Formula 4> 상기 식중 R3, R4, 및 R5는 청구항 제3항에서 정의한 바와 같다.Wherein R 3 , R 4 , and R 5 are as defined in claim 3. 제1항 또는 제4항에 있어서, 상기 산화시키는 단계가 O3, K2Cr2O7 , Na2Cr2O7, KMnO4, NaIO4, Pb(OC(=O)CH3)2, RuO4, H2O 2, RuCl3, CrO3, (C5H5NH)2Cr2 O7(PDC), 피리디움클로로크로메이트(PCC), NaClO2, Hg(OC(=O)CH3)2로 이루어진 군에서 선택된 하나 이상의 산화제를 이용하여 실시되는 것을 특징으로 하는 방법.The method according to claim 1 or 4, wherein the oxidizing step is O 3 , K 2 Cr 2 O 7 , Na 2 Cr 2 O 7 , KMnO 4 , NaIO 4 , Pb (OC (═O) CH 3 ) 2 , RuO 4 , H 2 O 2 , RuCl 3 , CrO 3 , (C 5 H 5 NH) 2 Cr 2 O 7 (PDC), pyridiumchlorochromate (PCC), NaClO 2 , Hg (OC (= O) CH 3 2 ) using at least one oxidant selected from the group consisting of. 제2항 또는 제3항에 있어서, 상기 환원시키는 단계가 NaBH4, LiBH4, LiAlH4, L-셀렉트라이드, 디이소프로필알루미늄하이드라이드(DIBAL), Zn(BH4)2, (CH3)4BH(OC(=0)CH3)3, NaBH3CN, LiBHEt3, LiAl(OC(=O)CH3)3로 이루어진 군에서 선택된 하나 이상의 환원제를 이용하여 실시되는 것을 특징으로 하는 방법.The method of claim 2 or 3, wherein the reducing step is NaBH 4 , LiBH 4 , LiAlH 4 , L-selectide, diisopropylaluminum hydride (DIBAL), Zn (BH 4 ) 2 , (CH 3 ) 4 BH (OC (= 0) CH 3 ) 3 , NaBH 3 CN, LiBHEt 3 , LiAl (OC (═O) CH 3 ) 3 , wherein the method is carried out using at least one reducing agent selected from the group consisting of: 제2항 또는 제3항에 있어서, 상기 환원 반응시 부분입체선택성을 증가시키기 위하여 CeCl3, ZnCl2, NiCl2, 및 SmCl3로 이루어진 군에서 선택된 촉매가 더 부가되는 것을 특징으로 하는 방법.The method according to claim 2 or 3, wherein a catalyst selected from the group consisting of CeCl 3 , ZnCl 2 , NiCl 2 , and SmCl 3 is further added to increase diastereoselectivity in the reduction reaction. 제1항 내지 제4항중 어느 한 항에 있어서, 상기 C1-C8의 알킬기가 메틸, 에틸, 프로필, 이소프로필, n-부틸, 이소부틸, 및 t-부틸로 이루어진 군에서 선택된 그룹인 것을 특징으로 하는 방법.The method according to any one of claims 1 to 4, wherein the C1-C8 alkyl group is a group selected from the group consisting of methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, and t-butyl. How to. 제1항 내지 제4항중 어느 한 항에 있어서, 상기 히드록시기의 보호기가 메톡시메틸, 메톡시티오메틸, 트리에틸실릴, 트리이소프로필실릴, t-부틸디페닐실릴, t-부틸디메틸실릴, 트리메틸실릴, 트리페닐실릴, 벤질, p-메톡시벤질, t-부톡시메틸, 테트라히드로피라닐, 3,4-디메톡시벤질, o-니트로벤질, 디페닐메틸, 및 트리페닐메틸로 이루어진 군에서 선택된 그룹인 것을 특징으로 하는 방법.The protecting group of the hydroxy group according to any one of claims 1 to 4, wherein the protecting group of the hydroxy group is methoxymethyl, methoxythiomethyl, triethylsilyl, triisopropylsilyl, t-butyldiphenylsilyl, t-butyldimethylsilyl, trimethyl In the group consisting of silyl, triphenylsilyl, benzyl, p-methoxybenzyl, t-butoxymethyl, tetrahydropyranyl, 3,4-dimethoxybenzyl, o-nitrobenzyl, diphenylmethyl, and triphenylmethyl The selected group. 제1항 내지 제4항중 어느 한 항에 있어서, 상기 아민기의 보호기가 아세틸, 벤조일, 트리페닐메틸, 알릴, 디(4-메톡시페닐)메틸, N-5-디벤조수베릴, (4-메톡시페닐)디페닐페닐, 및 9-페닐플루오로레닐로 이루어진 군에서 선택된 그룹인 것을 특징으로 하는 방법.The protecting group of the amine group according to any one of claims 1 to 4, wherein the protecting group of the amine group is acetyl, benzoyl, triphenylmethyl, allyl, di (4-methoxyphenyl) methyl, N-5-dibenzosuberyl, (4 -Methoxyphenyl) diphenylphenyl, and 9-phenylfluororenyl. 제1항 내지 제4항중 어느 한 항에 있어서, 상기 C1-C20의 알킬기가 메틸, 에틸, 프로필 이소프로필 부틸, 이소부틸, t-부틸, 헥실, 및 헵틸로 이루어진 군에서 선택된 그룹인 것을 특징으로 하는 방법.The method according to any one of claims 1 to 4, wherein the C1-C20 alkyl group is a group selected from the group consisting of methyl, ethyl, propyl isopropyl butyl, isobutyl, t-butyl, hexyl, and heptyl. How to. 제1항 내지 제4항중 어느 한 항에 있어서, 상기 C3-C20의 사이클로알킬기가 사이클로프로필, 사이클로부틸, 사이클로펜틸, 및 사이클로헥실로 이루어진 군에서 선택된 그룹인 것을 특징으로 하는 방법.5. The method of claim 1, wherein the cycloalkyl group of C 3 -C 20 is a group selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. 6.
KR10-2001-0082479A 2001-12-21 2001-12-21 Method of synthesizing β-amino-α-hydroxy carboxylic acid and its derivatives KR100473802B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR10-2001-0082479A KR100473802B1 (en) 2001-12-21 2001-12-21 Method of synthesizing β-amino-α-hydroxy carboxylic acid and its derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR10-2001-0082479A KR100473802B1 (en) 2001-12-21 2001-12-21 Method of synthesizing β-amino-α-hydroxy carboxylic acid and its derivatives

Publications (2)

Publication Number Publication Date
KR20030052494A KR20030052494A (en) 2003-06-27
KR100473802B1 true KR100473802B1 (en) 2005-03-08

Family

ID=29577258

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2001-0082479A KR100473802B1 (en) 2001-12-21 2001-12-21 Method of synthesizing β-amino-α-hydroxy carboxylic acid and its derivatives

Country Status (1)

Country Link
KR (1) KR100473802B1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3962319A (en) * 1972-01-19 1976-06-08 Badische Anilin- & Soda-Fabrik Aktiengesellschaft α-Hydroxy-β-aminocarboxylic acids
US5883284A (en) * 1995-10-04 1999-03-16 Ajinomoto Co., Inc. Method for producing α-hydroxy-β-aminocarboxylic acids
US5932758A (en) * 1995-07-04 1999-08-03 Degussa Aktiengesellschaft Process for the production β-amino-α-hydroxycarboxylic acids and derivatives thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3962319A (en) * 1972-01-19 1976-06-08 Badische Anilin- & Soda-Fabrik Aktiengesellschaft α-Hydroxy-β-aminocarboxylic acids
US5932758A (en) * 1995-07-04 1999-08-03 Degussa Aktiengesellschaft Process for the production β-amino-α-hydroxycarboxylic acids and derivatives thereof
US5883284A (en) * 1995-10-04 1999-03-16 Ajinomoto Co., Inc. Method for producing α-hydroxy-β-aminocarboxylic acids
US6169200B1 (en) * 1995-10-04 2001-01-02 Ajinomoto Co., Inc. Method for producing α-hydroxy-β-aminocarboxylic acids

Also Published As

Publication number Publication date
KR20030052494A (en) 2003-06-27

Similar Documents

Publication Publication Date Title
US8436194B2 (en) Process for the preparation of prostaglandin analogues and intermediates thereof
KR19980018089A (en) Stereoselective Preparation of Transazetidinone
KR20040043169A (en) Process for the production of beraprost and its salts
KR20020060988A (en) Method For The Stereoselective Synthesis Of Cyclic Amino Acids
KR100473802B1 (en) Method of synthesizing β-amino-α-hydroxy carboxylic acid and its derivatives
KR100205767B1 (en) Stereoselective preparation method of azetidinone
CN111777538A (en) Preparation method of bimatoprost
WO2002012230A1 (en) Intermediate of carbapenem antibiotics and process for the preparation thereof
KR100915551B1 (en) Process for the efficient preparation of 3-hydroxy pyrrolidine and derivatives thereof
JP4742239B2 (en) Bicyclo [3.1.0] hexane derivative and method for producing the same
JP2004534040A (en) Stereoselective synthesis of 2-hydroxy-4-phenylbutyrate
US20100317868A1 (en) Method of preparing taxane derivatives and intermediates used therein
US6515126B2 (en) Chemical synthesis of spirocyclic piperidines by double ring-closing metathesis
US6677465B2 (en) Method for the enantioselective preparation of 3,3-diphenyl-2,3-epoxy propionic acid esters
KR0182192B1 (en) Selective process for preparing optically active (3r,4s)-3-alkoxy-4-phenyl-2-azetidinone
KR100225534B1 (en) Stereospecific process for preparing (2r,3s)-beta--phenylisoserine
JPH10231280A (en) Production of 3-amino-2-hydroxy-4-phenylbutylonitrile derivatives
KR100267596B1 (en) Method for stereoselective synthesis of oxazoline derivatives equivalent to beta-amino-lpha-hydroxy acid
KR100518933B1 (en) Method for purifying Oxazoline- azetidinone derivative
JP3740783B2 (en) Process for producing 4- (2-alkenyl) -2,5-oxazolidinediones
JP4267107B2 (en) Pyridine derivative and method for producing the same
US6388097B1 (en) Process for the preparation of β hydroxy-δ lactone using novel intermediates
JP4591778B2 (en) Process for producing α, β, γ-substituted cyclopentanone derivatives
US7759492B2 (en) Enantioselective synthesis of 13-oxotricyclo[8.2.1.0.3,8] trideca-3(8),4,6-triene-5-carboxylates
EP1234884B1 (en) A process for the preparation of beta-hydroxy-delta-lactone using novel intermediates

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20100219

Year of fee payment: 6

LAPS Lapse due to unpaid annual fee